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Protein kinases (PKs) are important cellular signalling molecules whose aber-
rance from normal activity can lead to several complex diseases, including can-
cer, cardiovascular diseases, or neurological disorders. This has made PKs 
important therapeutic targets (Cohen 2002; Knight et al. 2010; Roskoski 2015). 
More than 30 small-molecule PK inhibitors have reached the drug market dur-
ing recent 15 years and a large number of new inhibitors of PKs are on various 
stages of clinical trials (Rask-Andersen et al. 2014; Wu et al. 2015; Fabbro et 
al. 2015). Additionally, inhibitors of PKs are useful reagents for studying and 
understanding of both the physiological role of PKs in normally functioning 
cells and biological mechanisms behind human diseases. Therefore, consider-
able effort has been put into development of reliable biochemical and cell-based 
assays to monitor the activity of PKs and screen their inhibitors. 
Fluorescence anisotropy (FA) and Förster-type resonant energy transfer 
(FRET) are common photoluminescence techniques that are used for character-
ising the activity of PKs and the association of PKs with inhibitors in biochemi-
cal as well as in biological assays. However, in complicated biological samples 
these methods may possess some drawbacks due to the background fluores-
cence of organic compounds or autofluorescence of cells that cannot be distin-
guished from the fluorescence signal related to the biological target under 
inspection. Hence, the application of photoluminescent probes that emit light 
with long decay time and enable the performance of measurements in time-
resolved (TR) mode has caused great progress with luminometry-based assays, 
which has led to improved assay formats to obtain more accurate and detailed 
information about the sample. 
In this thesis, the research on the conjugates of adenosine analogues and 
arginine-rich peptides (ARCs) led us from bisubstrate inhibitors to fluorescent 
probes for biochemical assays, PK binding-responsive long-lifetime photolumi-
nescent probes, and regulators of protein phosphorylation balances in living 
cells. New structural fragments were introduced into ARCs and the compounds 
were characterised and reconstructed in order to further improve their affinity 
and selectivity towards different basophilic PKs, and increase resistance of the 
compounds to enzymatic degradation to widen their biological applications. 
Thereafter, the newly constructed and characterised compounds were applied 
for developing effective assay systems for the investigation of PKs and their 
inhibitors in biological solutions with the aid of the TR measurement tech-
niques. In the course of this study binding-responsive long-lifetime photolumi-
nescent probes were discovered and developed into unique research tools. 
Moreover, for the first time, inhibitory potency of ARCs in the living cells was 
measured. The results of these measurements reveal the potential of ARCs for 
the regulation of activity of PKs in cells and point to the structural changes that 
should be performed to improve the potency and selectivity of the inhibitors for 




1. LITERATURE OVERVIEW 
1.1. Protein kinases 
Protein phosphorylation has essential role in cell life. It allows cells to be 
responsive to their external environment, regulating signalling pathways and 
cellular processes that mediate metabolism, growth, division, differentiation, 
membrane transport, apoptosis, intracellular communication, etc. (Manning et 
al. 2002a; Johnson 2009). PKs, belonging to the transferase class of enzymes, 
catalyse the phosphorylation of proteins. The phosphorylation event is preceded 
by binding of a nucleotide [usually adenosine 5’-triphosphate (ATP)] and the 
target protein to the active site of the enzyme. Thereafter, the γ-phosphoryl 
group of ATP is transferred to a serine, threonine, or tyrosine residue of the 
substrate protein, which causes changes in its activity, localisation, or interac-
tions with other proteins (Schwartz and Murray 2011). Protein phosphatases, on 
the other hand, catalyse protein dephosphorylation, removal of phosphoryl 
groups from phosphoproteins via hydrolysis. 
PKs form a large enzyme superfamily that carries a huge role in cell signal 
transduction. There are more than 500 PK genes identified in the human 
genome, representing about 2.7 % of all human protein-coding genes (Hunter 
2000; Manning et al. 2002a; Schwartz and Murray 2011). The human kinases 
are classified into a hierarchy of groups, families, and subfamilies based on the 
comparison of the amino-acid sequences of the catalytic domains, biological 
functions, and substrate specificities. According to that, it is possible to distin-
guish nine main groups of PKs (Hanks and Hunter 1995; Manning et al. 2002b; 
Hanks 2003), which are briefly introduced in the subsequent section. 
The TK (tyrosine kinase) group constitutes of a large number of enzymes 
that specifically phosphorylate proteins at tyrosine residues. PKs of the AGC 
group, on the other hand, are basic amino acid directed enzymes (PKA, PKG, 
PKC) phosphorylating substrates at serine or threonine residues that possess 
arginine and lysine residues in close proximity. The CaMK (calcium/ 
calmodulin dependent protein kinase) group incorporates the family of PKs 
regulated by calcium/calmodulin. These PKs also favour substrates that are rich 
in basic amino acid residues. The CMGC group includes enzymes that are 
proline-directed, phosphorylating substrates at the sites lying in proline-rich 
environments, e.g., CDK (cyclin-dependent kinase), MAPK (mitogen-activated 
protein kinase), GSK (glycogen synthase kinase), and CLK (CDC2-like kinase) 
families. The STE group is named after homologs of yeast Sterile 7, Sterile 11, 
and Sterile 20 kinases, containing PKs of MAPK cascade families. The CK1 
group is named after casein kinase 1 and consists of CK1, TTBK (tau tubulin 
kinase), and VRK (vaccinia-related kinase) families, which preferably phos-
phorylate motifs rich in acidic residues. The TKL (tyrosine kinase-like) group 
constitutes various families that resemble both tyrosine and serine-threonine 
kinases, like MLK (mixed-lineage kinase) and IRAK (interleukin-1 receptor-




pseudokinases with similar domain sequence to tyrosine kinases. Lastly, there 
exists a group of atypical kinases in human genome, which contains proteins that 
have been reported to have biochemical kinase activity, without having sequence 
similarity to the above-mentioned PK domains and their close homologs. 
 
 
1.1.1. AGC protein kinases 
The AGC group was named after three representative families of PKs, cAMP-
dependent protein kinase (PKA), cGMP-dependent protein kinase (PKG) and 
protein kinase C (PKC) (Hanks and Hunter 1995). This group contains more 
than 60 PKs that are divided into 14 families and 21 subfamilies according to 
their different functional domains, which are important for the activity and 
localisation of the PK (Manning et al. 2002b; Pearce et al. 2010; Arencibia et 
al. 2013). More complexity to this group is added by multiple isoforms and 
splice variants. 
The activity of the AGC kinases is regulated by the local concentrations of 
cytoplasmic second messengers, such as cyclic adenosine 3’,5’-monophosphate 
(cAMP) and lipids, and by the phosphorylation of two highly conserved regu-
latory motifs (T- or activation loop in the catalytic domain and hydrophobic 
motif in a non-catalytic region following the kinase domain) (Pearce et al. 
2010). For some PKs the phosphorylation at turn motif may be crucial for their 
stability and integrity (Pearce et al. 2010; Arencibia et al. 2013). 
The AGC group includes some widely studied PK families (PKA, PKG, 
PKC, PKB/Akt, MSK, RSK, ROCK, etc.), while several of them may catalyse 
phosphorylation of the same proteins. This is due to their similar substrate con-
sensus sequence preferences as these PKs tend to be basic amino acid directed 
enzymes, phosphorylating substrates at serine or threonine residues flanking by 
arginine and lysine residues (Pearce et al. 2010). PKs of AGC group carry a key 
role in several important intracellular signalling pathways and are therefore 
potential targets for the treatment of variety of diseases, like cancer, diabetes, 
neurological disorders, cardiovascular diseases, inflammation, and viral infec-
tions (Pearce et al. 2010; Arencibia et al. 2013). 
Fasudil, an inhibitor of ROCK kinase, was the first clinically applied PK 
inhibitor, used for the treatment of subarachnoid haemorrhage-induced cerebral 
vasospasm in Japan since 1995 (Asano et al. 1998; Tamura et al. 2005). Recent 
evidence indicate that fasudil could also display therapeutic effect on control-
ling central nervous system disorders, such as Alzheimer’s disease (Chen et al. 
2013). Currently, the first generic inhibitor of AGC kinases, AT13148, is in 
clinical trials. It is a potent inhibitor of ROCK, PKA, and PKB/Akt kinases 
(Yap et al. 2012). The effectiveness of AT13148 has been demonstrated in case 
of ROCK-mediated functions in melanoma cells and in case of gastric cancer 
where PKB/Akt and other AGC family kinases are dysregulated (Sadok et al. 
2015; Xi et al. 2016). Moreover, AT13148 has also the potential to reduce the 




the adrenal Cushing’s syndrome and the activity of PKA, where the L205R 
(Lysine205 → Arginine) mutation in the catalytic subunit promotes constitutive 
activation of the kinase (Cao et al. 2014). Therefore, inhibition of multiple AGC 
kinases may lead to even better anti-tumour activity and minimizes clinical 
resistance to the drug (Xi et al. 2016; Yap et al. 2012). 
 
 
1.1.2. cAMP-dependent protein kinase 
The cAMP-dependent protein kinase (PKA) was discovered and first character-
ised in 1968 (Walsh et al. 1968) and it has been thoroughly studied since. PKA 
is the best characterised PK, mainly due to its simplicity of production and rela-
tively simple dissociative mechanism of activation, being therefore as a proto-
type for other PKs (Taylor et al. 2012). In addition, the catalytic subunit of PKA 
(PKAc) was also the first PK, whose crystal structure was solved, explaining 
the role of the highly conserved regulatory motifs and revealing the organiza-
tion of PKs (Knighton et al. 1991a). 
The activity of PKA is mainly controlled by an intracellular second messen-
ger, cAMP. In the absence of cAMP, PKA exists as an inactive tetrameric holo-
enzyme complex, composing of two regulatory (PKAr) and two catalytic 
(PKAc) subunits. The binding of 4 cAMP molecules to the dimer of PKAr sub-
units leads to the reduction in affinity between PKAr and PKAc subunits and 
the holoenzyme dissociates into the dimer of the PKAr subunits and two cata-
lytically active monomers of PKAc (Skålhegg and Taskén 2000). 
The subunits of PKAc and PKAr are relatively small proteins (MW-s of 40 
kDa and 50-57 kDa, respectively) and in the human genome, there are 5 genes 
encoding the PKAc subunits (PKAcα, PKAcβ, PKAcγ, PRKX, and PRKY) and 
four genes that encode the PKAr subunits (PKArIα, PKArIβ, PKArIIα, and 
PKArIIβ) (Cheng et al. 2001; Zhang et al. 2004; Hanks 2003; Tasken 2004; 
Turnham and Scott 2016). Both isoforms, PKArI and PKArII comprise a 
dimerization/docking domain, a region responsible for interaction with the 
PKAc subunit at the amino terminus, and two tandem cAMP binding sites at the 
carboxyl terminus (Taylor et al. 2004; Kim et al. 2006). To form a holoenzyme 
complex, the type II subunits are autophosphorylated by catalytic subunits and 
act as true substrates, whereas type I subunits are not phosphorylated and they 
act as pseudosubstrates by inhibiting the activity of PKA (Johnson et al. 2001; 
Taylor et al. 2012). The PKAc subunit is a globular protein with two lobes that 
are common for all AGC kinases. The smaller, amino terminal lobe is domi-
nated by β-strands and is associated mostly with the binding of ATP. The larger, 
carboxyl terminal lobe mainly consists of α-helices and is involved in sub-
strate/peptide binding and phosphoryl transfer (Taylor et al. 1999). PKAc has 
open and closed conformations and in order to be fully catalytically active, it 
needs to be phosphorylated at Thr197 and autophosphorylated at Ser338 
(Johnson et al. 2001). Thereafter, active PKAc mediates cellular responses in 




1.1.3. The signalling through PKA pathway and its regulation 
PKA is a widely examined kinase responsible for phosphorylating a broad array 
of downstream substrates. It is considered as an essential regulator in many cell 
signalling events (e.g., regulation of intracellular calcium concentration or gene 
transcription) (Tasken 2004; Turnham and Scott 2016). The PKA-based signal-
ling pathway is known to be activated by a number of different hormones, neu-
rotransmitters, and other signalling substances that bind to G-protein coupled 
cell-membrane receptors (GPCR) (Skålhegg and Taskén 2000). These extra-
cellular stimuli activate the G-proteins, which then regulate the activation of 
adenylate cyclase (AC). The subsequent production of cAMP, which acts as the 
major activator of PKA, leads to the dissociation of regulatory and catalytic 
subunits. Thereafter, the activated catalytic subunits can catalyse the phosphor-
ylation of a variety of cytosolic and nuclear substrates, including GSK, glyco-
gen phosphorylase kinase, nuclear cAMP-response element-binding protein 
(CREB), cAMP-responsive modulator (CREM), and cAMP-dependent tran-
scription factor ATF1 (Smith et al. 1999; Mayr et al. 2001; Johannessen et al. 
2004a; Sassone-Corsi 2012). 
CREB was one of the first transcription factors whose activity was shown to 
be regulated by phosphorylation (Shaywitz and Greenberg 1999; Mayr et al. 
2001). It is a member of the closely related CREB/ATF1/CREM family of tran-
scription factors, sharing high similarity in their amino acid sequences and 
functional domains (Mayr et al. 2001). CREB binds as a dimer to the cAMP-
response elements (CREs) with the conserved TGACGTCA sequence, which is 
present in the promoter of many cAMP-responsive genes (Johannessen et al. 
2004b; Carlezon et al. 2005). Phosphorylation of CREB allows association with 
the general transcriptional co-activators: CREB binding protein (CBP) and its 
paralogue p300. The formed complex interacts with RNA polymerase II, stim-
ulating the transcription of DNA and production of protein (Mayr et al. 2001; 
Johannessen et al. 2004b). CREB (as well CREM and ATF1) can be phos-
phorylated by many kinases. It has potential phosphorylatable sites for several 
kinases, like Ser133 residue for PKA, CaMK, MAPKAPK (mitogen-activated 
protein kinase-activated protein kinase), and PKB/Akt; Ser142 for CaMKII; 
Ser98 for CaMKIV; and Ser129 for GSK3 kinase. Overall, more than 20 
different PKs that have been shown to phosphorylate CREB (Johannessen et al. 
2004a; Johannessen and Moens 2007). 
Additionally, the signalling through PKA pathway can be regulated by the 
A-kinase anchoring proteins (AKAPs). AKAPs belong to a large family of pro-
teins that influence subcellular localisation of PKA by interacting with the reg-
ulatory subunits. They bring specificity into cAMP-mediated signal transduc-
tion by placing PKA close to specific effectors and substrates. Specific AKAPs 
for both PKArI and PKArII subunits have been described, whereas PKArII 
subunits show considerably higher affinity than PKArI subunits (Tasken 2004). 
AKAPs can regulate PKA activation by bringing PKA near to the stimulation 




(e.g., phosphodiesterases) or for the proteolysis of PKAr subunits (e.g., calpain) 
(Shell and Lawrence 2012). 
Natural inhibitors of PKA are important regulators of the activity of PKAc. 
These inhibitors that bind with high affinity and are specific to the PKAc belong 
to two protein families: the heat-stable protein kinase inhibitors (PKIs) and the 
PKAr-s (Johnson et al. 2001). Type I PKAr and PKI proteins comprise pseudo-
substrate consensus sequences where the phosphoacceptor site is an alanine 
residue rather than serine or threonine. Also, both pseudosubstrates require two 
magnesium ions and ATP to form a tight complex with PKAc (Knighton et al. 
1991b; Cheng et al. 2001). PKI inhibits PKAc in the presence of cAMP, while 
it mediates nuclear export of active PKAc, preventing its association with other 
substrates in signal transduction pathways (Fantozzi et al. 1992). PKAr subunits 
control PKAc activity depending on the levels of cAMP and supress the activity 
of catalytic subunit in the absence of secondary messengers (Johnson et al. 
2001; Taylor et al. 2012). 
 
 
1.2. Inhibitors of protein kinases 
PKs have critical role in cell signalling pathways, whereby aberrant PK activity 
may lead to tumour formation. Therefore, PKs are important targets for cancer 
drug development by pharmaceutical companies (Cohen 2002; Knight et al. 
2010). Intense efforts have been made to develop specific PK inhibitors as 
therapeutic agents or as biological tools for diagnosis and monitoring PK-
related diseases in their early stages (Wang et al. 2007; Kasari et al. 2012). 
Drug development efforts have resulted in a remarkable success: more than 30 
small-molecule PK inhibitors have reached the drug market (Rask-Andersen et 
al. 2014; Wu et al. 2015; Fabbro et al. 2015; Sharma et al. 2016). Encouraged 
by the progress, a large number of new inhibitors of PKs have been taken to 
various stages of clinical development (Gonzalez de Castro et al. 2013). The 
majority of kinase inhibitors are targeted towards tyrosine kinases (e.g., 
Gleevec® - the first approved small-molecule tyrosine-kinase inhibitor) (Savage 
and Antman 2002), however serine/threonine kinases belonging to the AGC 
group are also of interest for pharmaceutical companies. 
In the active site PKs possess specific binding sites for the substrate protein 
and ATP. Hence, the following active site-directed reversible inhibitors of PKs 
can be distinguished: ATP-site directed inhibitors, peptide/protein substrate-site 
directed inhibitors, and bisubstrate-analogue inhibitors. Additionally, allosteric 
inhibitors regulate kinase activity by binding to an allosteric site of the PK 
(Schwartz and Murray 2011). 
A great majority of reported PK inhibitors are directed to the ATP-binding 
site. The first series of potent ATP-competitive inhibitors, isoquinolinesulfona-
mide derivatives (known as H-series inhibitors or Hidaka’s inhibitors), was 
developed in early 1980s (Hidaka et al. 1984). Earlier compounds were rela-




pounds led to more active and selective inhibitors (Ono-Saito et al. 1999). One 
of the compounds, H89, has been widely used as a PKAc-selective compound, 
while HA1077 (fasudil) is known as a selective inhibitor of ROCK kinase. 
Fasudil was also the first clinically applied PK inhibitor for the treatment of 
subarachnoid haemorrhage-induced cerebral vasospasm in Japan in 1995 
(Asano et al. 1998; Tamura et al. 2005). In addition, several successful ATP-
competitive inhibitors based on pyridine derivatives (e.g., ROCK inhibitor Y-
27632), aminofurazan derivatives (e.g., PKB/Akt inhibitor GSK690693) and 
phenylpyrazole derivatives (e.g., multi-AGC inhibitor AT13148) have been 
developed and taken to clinical trials (Uehata et al. 1997; Rhodes et al. 2008; 
Okumura et al. 2015; Xi et al. 2016; Nitulescu et al. 2016). 
However, ATP-site targeted drugs are known to have selectivity problems as 
all PKs, together with other proteins of the purinome (3266 purine-binding 
proteins in human) bind purine (a structural constituent of ATP) and its deriva-
tives (Haystead 2006; Knapp et al. 2006). Moreover, a serious disadvantage of 
ATP-competitive inhibitors is that they have to compete with high intracellular 
concentration of ATP (1–5 mM) (Beis and Newsholme 1975; Ando et al. 2012). 
As the structure of peptide/protein substrate-binding domain of kinases is 
more variable than that of the ATP site, relatively selective peptide-based 
inhibitors have been described (Bogoyevitch et al. 2005; Harrison et al. 2008). 
However, in order to achieve high inhibitory potency, longer peptidic structures 
are needed. This is due to the nature of peptide/protein substrate-binding site 
where interactions appear to involve larger and less well-defined contact area. 
Resulting compounds possessing higher molecular weight lead to the problems 
with cellular transport and proteolytic stability (Bogoyevitch et al. 2005; Breen 
et al. 2014). 
In recent years the bisubstrate approach has gained popularity for the con-
struction of potent and selective inhibitors of PKs (Parang and Cole 2002; 
Lavogina et al. 2010a; Stebbins et al. 2011; Lamba and Ghosh 2012). Bisub-
strate inhibitors (also known as bisubstrate analogue inhibitors) consist of two 
conjugated fragments, each targeting one binding site of a particular substrate. 
This approach enables the incorporation of additional interaction points into the 
inhibitor to afford contacts to a less-conserved peptide/protein substrate-binding 
site of the kinase (Lavogina et al. 2010a). Thus, the two important biochemical 
characteristics of a good inhibitor, affinity and selectivity, can be easily 
improved. However, the cellular transport of those compounds is still an 
obstacle to overcome. 
 
 
1.2.1. ARC-based bisubstrate inhibitors 
ARCs are conjugates of hydrophobic heteroaromatic fragments (binding to the 
ATP site of the PK) and peptide analogues (binding to the peptide/protein sub-
strate site of the PK), connected via a linker chain with optimized structure 




acronym ARC is derived from the first generation of ARC-based bisubstrate 
inhibitors, called Adenosine analogue (A) and arginine (R)-rich peptide conju-
gates (C) (Enkvist et al. 2006). Although, far-reaching changes have been intro-
duced to the nucleoside-mimetic and peptidic moieties, the acronym has been 




Figure 1. Example of a third generation ARC-based bisubstrate inhibitor (ARC-1028). 
The nucleosidic part of the inhibitor is surrounded with the red ellipse, the linkers are 
rounded by the blue rectangle, the chiral spacer is placed in the green polygon, and the 
peptidic part in the magenta rectangle (Lavogina et al. 2010a). 
 
 
Extensive structure–affinity studies and X-ray analysis of ARC/PK co-crystals 
have been used to develop highly potent ARC-inhibitors towards several baso-
philic and acidophilic PKs (Ki values in low nanomolar or subnanomolar range 
have been obtained towards PKA, PKB/Akt, ROCK, PIM, and CK2 kinases) 
(Enkvist et al. 2006; Lavogina et al. 2009; Lavogina et al. 2012; Enkvist et al. 
2012; Ekambaram et al. 2013). The first substantial structural change in the 
structures of ARC-based inhibitors, which significantly increased their affinity 
towards different basophilic PKs was the replacement of the L-amino acid resi-
dues with D-amino acids in the linker and peptidic moiety. This structural modi-
fication was also contributing to the stability of the conjugates towards proteol-
ysis (Enkvist et al. 2006). Subsequently, better interactions with the target 
kinases was obtained by the introduction of a chiral spacer that tethered two 
flexible linkers (Lavogina et al. 2009; Pflug et al. 2010). 
So far, the affinity and selectivity of ARC-inhibitors has been improved by 
varying the nucleoside-mimicking moiety and/or linkers with or without chiral 
spacers, while the oligoarginine peptide has served as a recognition fragment 
for basophilic PKs. Still, some important modifications have been introduced 
into the peptidic moiety. Recently, a conjugate for mitotic kinase Haspin was 
reported, that was comprising an aromatic fragment targeted to the ATP-site 
and a peptide mimicking the N-terminus of histone H3 targeted to the substrate 
protein site (Kestav et al. 2015). Moreover, the bisubstrate approach has been 
successfully used for the development of inhibitors of an acidophilic kinase 




comprising several aspartic acid residues or negatively charged peptoids 
(Enkvist et al. 2012; Viht et al. 2015). 
ARC-inhibitors have found applicability in variety of assays, mainly due to 
their high inhibitory potency and affinity, whereas the later property is 
preserved after labelling of ARCs with fluorescent dyes or immobilizing to the 
chip surface of a biosensor (Viht et al. 2007; Vaasa et al. 2009). The arginine-
rich transport peptides in the structure of ARCs give them cell plasma 
membrane-penetrative properties (Uri et al. 2002; Räägel et al. 2008). 
Additionally, intensive cellular uptake has been demonstrated for ARCs 
labelled with fluorescent dyes (ARC-Fluo probes), which supports the 
application of ARC-derived fluorescent probes for mapping and monitoring 
kinase activity in living cells (Vaasa et al. 2010). 
 
 
1.2.2. Cellular transport of protein kinase inhibitors 
In addition to the inhibitory potency, two other critical factors that affect the 
success of a compound as a PK-inhibitor-based cancer drug are its effective 
cellular accumulation and the appropriate intracellular localisation. Addition-
ally, cell plasma membrane-permeable chemical inhibitors could be valuable 
tools for studying cellular functioning of PKs. 
Small-molecule hydrophobic PK inhibitors have usually good cell plasma 
membrane permeability. For instance, the success of the cancer drug imatinib 
(Gleevec®) might be explained by its intense intracellular accumulation 
(Widmer et al. 2006; Lipka et al. 2012; Berglund et al. 2014), thereby the 
mechanism responsible for its intense uptake is still not clear (Nies et al. 2014). 
Because of unfavourable physico-chemical properties (negatively charged and 
polar) and low proteolytic stability of initial peptide-derived and phosphate-
comprising bisubstrate inhibitors, their effect on living cells and cell plasma 
membrane permeability has been shown only in a limited number of publica-
tions in recent years (Räägel et al. 2008; Stebbins et al. 2011; Lamba and 
Ghosh 2012; van Wandelen et al. 2013). 
One of the possibilities to overcome the issue of limited cellular transport of 
polar compounds is the application of cell-penetrating peptides (CPPs). CPPs 
are relatively short (< 30) amino acid sequences, capable for penetration of cell 
plasma membrane and transporting bioactive cargos (plasmid DNAs, oligonu-
cleotides, siRNAs, therapeutic proteins/peptides, nanoparticles, etc.) into cells 
either in a covalent or non-covalent manner (Heitz et al. 2009; Koren and 
Torchilin 2012; Ramsey and Flynn 2015). Various protein derived (penetratin, 
Tat-peptide), chimeric (transportan), and synthetic (oligoarginines) transport 
peptide sequences have been described (Derossi et al. 1994; Vives et al. 1997; 
Pooga et al. 1998; Futaki et al. 2001), whereas most common CPPs are poly-





Although the cell internalization of CPPs may depend of various character-
istics of the compounds and the origin of the cells, at least two main cellular 
uptake mechanisms can be distinguished: direct membrane translocation and 
endocytic pathways (macropinocytosis, clathrin-mediated endocytosis, caveo-
lae/lipid-raft-mediated endocytosis, and caveolae-independent endocytosis) 
(Duchardt et al. 2007). For cationic arginine-rich CPPs it has been suggested 
that endocytosis (macropinocytosis and clathrin/caveolae-mediated endocytosis) 
has major role in the cellular uptake, while direct cell plasma membrane pene-
tration is dependent on peptide concentration and incubation conditions (Futaki 
2006; Duchardt et al. 2007; Brock 2014).  
Intracellular activity of the CPP transported cargo may be highly dependent 
on its endosomal escape. Therefore, a number of different strategies have been 
purposed for achievement of improved delivery of the cargos into cytoplasm or 
intracellular compartments, including lipidation of the CPPs (El-Sayed et al. 
2009; Lee and Tung 2010; Erazo-Oliveras et al. 2012). For example, it has been 
demonstrated that oligoarginine peptides modified with fatty acid moieties  
(N-myristoylation or N-acylation with other fatty acids) possess much better 
cellular uptake than their non-acylated arginine-rich peptide counterparts 
(Nelson et al. 2007; Lee and Tung 2010; Lee and Tung 2012). Moreover, as the 
awareness of different transport mechanisms that initiate endocytic processes 
(e.g., membrane receptor-mediated transport) has increased (Letoha et al. 2010; 
Kawaguchi et al. 2016), therefore considering those findings when designing 
new delivery systems that would be efficient for cellular uptake of arginine-rich 
CPPs is also important. 
Some CPPs (bioportides) possess bioactivity on their own (by this definition 
arginine-rich ARCs are also bioportides, but although high inhibitory potency of 
ARCs towards PKs was disclosed much earlier than the term bioportide was 
introduced, ARCs have not been reported as bioportides in relevant literature) 
and therefore they are used directly as research tools or therapeutic/diagnostic 
agents (Vasconcelos et al. 2013; Lukanowska et al. 2013; Jones et al. 2016). 
 
 
1.2.3. Characterisation of protein kinase inhibitors 
In order to assess the potency of PK inhibitors mainly two types of biochemical 
assay can be distinguished: kinetic inhibition assays and equilibrium binding 
assays (Jia et al. 2008; Smyth and Collins 2009). Both assay technologies have 
found applicability in screening of PK inhibitors. However, depending on their 
advantages and drawbacks, some methods are more preferred than others. 
Traditionally, kinetic inhibition assays were preferred for screening of PK 
inhibitors as they enable direct detection of phosphorylation of the substrate 
peptide/protein by a kinase of interest. PK inhibitors are characterised by 
determining their inhibitory effect on the rate of the kinase-catalysed phosphor-
ylation reaction of the peptide/protein substrate, which can be monitored in 




inhibition assay, main requirements include the availability of a suitable sub-
strate for phosphorylation, sufficient catalytic activity of the kinase, and specific 
reagents for monitoring of the phosphorylation reaction (Lebakken et al. 2009). 
For quantification of the phosphorylated substrate and detection of the inhibi-
tion of the phosphorylation activity of kinase, common techniques involve 
radioactive [γ-32P]-ATP, fluorescently labelled peptide substrates, specific 
phosphopeptide antibodies, or separation-based procedures for simultaneous 
monitoring of phosphorylated and non-phosphorylated substrates (Olive 2004; 
Jia et al. 2008; Smyth and Collins 2009). However, these methods can be 
expensive, time-consuming, and too complicated for development of high 
throughput screening (HTS) assays. Therefore, screening platforms which 
determine binding of the inhibitor to the PK not paying attention to the rate of 
PK-catalysed phosphorylation reaction have become increasingly popular 
(Lebakken et al. 2009; Vaasa et al. 2009; Rudolf et al. 2014). 
Competitive binding assays are progressively used for screening PK inhibi-
tors. Generally, these assays involve fluorescently labelled compounds (fluores-
cent probes/ligands) that bind to the ATP-binding site of the PK (Lebakken et 
al. 2007). Thereafter, either the direct binding of a labelled compound is meas-
ured or the displacement of the labelled probe from its complex with the kinase 
by an unlabelled inhibitor is examined (Vaasa et al. 2009; Ansideri et al. 2016). 
For detection of the binding (or displacement) of the probe, the changes in the 
photoluminescent characteristics (e.g., intensity, lifetime, polarization) of the 
system are usually determined (Huang 2003; Lebakken et al. 2007; Uri et al. 
2010; Slatter et al. 2013). These assays do not give information about the cata-
lytic properties of the enzyme, but reveal whether binding of the probe would 
be disturbed in the presence of the inhibitor (Lavogina et al. 2010a). Most of 
fluorescence-based binding assays in active use are homogeneous and allow 
quick measurements in HTS format (Lea and Simeonov 2011). However, the 
applicability of these assays may be restricted if the reporter probes do not pos-
sess sufficiently high affinity towards the target kinase (Huang 2003; Vaasa et 
al. 2009). On the other hand, special heterogeneous assays based on the applica-
tion of non-fluorescent detection techniques (e.g., surface plasmon resonance) 
may have great value for performing precise measurements as well (Viht et al. 
2007). 
For the characterisation of inhibitors, the IC50 values are in wider use. In 
case of an inhibition assay IC50 value represents the concentration of the inhib-
itor that causes 50 % reduction of the enzymatic/catalytic activity of the PK at 
specific concentration of the substrate. For a displacement assay, IC50 value is 
the concentration of the inhibitor at which 50 % of the probe is displaced from 
its complex with the PK. In both cases, the IC50 value is dependent on the con-
ditions used in the assay (e.g., the origin of the substrate or probe, the concen-
tration of the substrate or probe, and the concentration of the PK) and may 
therefore vary for a specific inhibitor in different experiments. In case of 




inhibition (Ki) or displacement (Kd) constants according to the Cheng-Prusoff 



























where [S] is the concentration of the substrate and Km is the Michaelis constant 
of the substrate. [L] is the concentration of the probe and KD is the dissociation 
constant of the complex between the probe and PK. 
For binding/displacement assays more suitable equations have been dis-
closed, which also consider the effect introduced by the protein concentration in 
the sample (equation 3) (Nikolovska-Coleska et al. 2004): 
 
 















where [L]50 is the concentration of free probe at 50 % displacement, [P]0 is the 
total concentration of PK, and KD is the dissociation constant of the complex 
between the probe and PK. 
 
 
1.3. Application of photoluminescence  
techniques in binding/displacement assays 
Photoluminescence-based assay methods are widely applied for different bio-
chemical as well biological applications. Photoluminescence is an optical emis-
sion of photons from molecule’s electronically excited states after absorption of 
photons. Depending on the nature of the excited state, photoluminescence is 
formally divided into two phenomena: fluorescence and phosphorescence 
(Lakowicz 2006). 
Following the light (photon) absorption, outer electrons of the luminophore 
molecules are excited from the ground state (S0) to some higher vibrational 
levels of the excited singlet state (S1 or S2) (Figure 2). Thereafter, the molecule 
rapidly relaxes through vibrational relaxation (VR) or internal conversion (IC) 
to the lowest vibrational level of S1. From the excited state S1, the molecule can 
return to the ground state (S0) either by emitting a photon in the form of fluores-
cence or by a radiationless mechanism, like energy dissipation as heat, colli-
sional quenching, or photobleaching. Due to the non-radiative processes 
between different vibrational levels of excited states and ground states, the 
emission of the luminophore occurs at lower energies (longer wavelengths) and 




emission spectra is called the Stokes shift. Additionally, the spin of an excited 
electron can be also reversed by intersystem crossing (ISC) to triplet state (T1), 
followed by radiationless processes or emission of a photon termed as phospho-
rescence. As a result of the spin reversion, the electron in the excited orbital has 
the same spin orientation as the ground-state electron. Therefore, the transition 
from the triplet excited state to the singlet ground state is formally forbidden 





Figure 2. The Jablonski diagram for photoluminescence (Hemmilä 1991). The diagram 
illustrates electronic states of a molecule (luminophore) and transitions between them. 
When a luminophore absorbs light (photon), its electrons are excited from the ground 
state (S0) to some higher vibrational levels of an excited singlet state (S1 or S2). The 
molecule rapidly relaxes through vibrational relaxation (VR) or internal conversion (IC) 
to lowest vibrational level of S1. Thereafter, it can return to the ground state (S0) either 
by emitting a photon in the form of fluorescence or without emission. The spin of an 
excited electron can also be reversed by intersystem crossing (ISC) to triplet state (T1), 




The lifetime (τ) of the excited state is defined by the average time the molecule 
spends in the excited state prior to return to the ground state. The value of τ 
depends on both the origin of the luminophore and its interactions with the local 
environment. Typical fluorescence lifetime is within the pico- to nanosecond 
range. As phosphorescence involves a spin forbidden process, the emission 
rates are slow and phosphorescence lifetimes are typically in the range of milli-
seconds to seconds (Lakowicz 2006). 
The development of a potential drug candidate from a PK inhibitor is time-
consuming and costly. Therefore, homogeneous photoluminescence-based 




PKs and their inhibitors, allowing more accurate, cost-effective and HTS meas-
urements. Most commonly applied techniques are based on the measurements 
of fluorescence intensity, fluorescence polarization/anisotropy (FP/FA), or effi-
ciency (FI) of Förster-type resonant energy transfer (FRET, also used as Förster 
resonance energy transfer), whereas the measurements can be performed in a 
steady-state or time-resolved (TR) mode. 
 
 
1.3.1. Fluorescence polarization/anisotropy 
FP/FA-based measurements are widely used in biochemical applications for the 
analysis of protein-protein, protein-DNA, or protein-ligand binding events 
(Lakowicz 2006). They are based on the photoselective excitation of fluoro-
phores by polarized light, where polarized light selectively excites those fluoro-
phore molecules whose absorption transition dipole is parallel to the electric 
vector of the excitation. This selective excitation results in a partially oriented 
population of fluorophores, and in partially polarized fluorescence emission. 
The degree of polarization is determined by the measurements of the emission 
light intensity vertically (ǁ) and horizontally (  ) to the excitation light plane, 





















The polarization and anisotropy are two representations of the same phenom-
enon and can be used interchangeably. The use of anisotropy is preferred as it is 
normalized by the total intensity. 
FA of the fluorescent probe correlates with its rotation speed and thus it is 
dependent on the molecular weight of the fluorophore-containing complex. A 
free small-molecule fluorescent probe is rotating rapidly and displaying a low 
value of anisotropy. On binding of the probe to the target biopolymer (e.g., PK) 
the size of the rotating unit increases, leading to a sharp rise in FA (Lakowicz 
2006; Demchenko 2015). 
Due to these features, FA-based measurements can be used for determination 
of binding affinity of the probe to the protein and for characterisation of unla-
belled inhibitors in displacement assays (Iyer et al. 2008; Vaasa et al. 2009; 
Ansideri et al. 2016). However, the affinity of a fluorescent probe limits the 
range of the inhibitor affinities that can be tested in the displacement assay 
(Huang 2003) and it also settles the lowest concentration of the binding protein 
that can be used in the FA-based assay. Moreover, the level of autofluorescence 
and other factors that affect the rate of rotational diffusion or binding of the 






1.3.2. Förster-type resonant energy transfer 
Some of the abovementioned drawbacks of FA-based measurements can be 
succeeded with the application of FRET-based assays. FRET is a non-radiative 
energy transfer from an excited donor (D) molecule to an acceptor (A) molecule 
in the ground state (Lakowicz 2006). The latter chromophore can be excited by 
this transferred energy and as a result the emission intensity of the donor is 
reduced and, instead, emission intensity of the acceptor is increased. The rate of 
energy transfer depends upon the extent of spectral overlap of the emission 
spectrum of the donor with the absorption spectrum of the acceptor, the quan-
tum yield of the donor, the relative orientation of the donor and acceptor transi-
tion dipoles, and the distance (usually in the range of 20 to 90 Å) between the 
donor and acceptor molecules (Lakowicz 2006). 
The transfer efficiency is typically measured by using either luminescence 
intensity (equation 6) or luminescence lifetime (equation 7) of the donor in the 














where the FIDA and FID are the fluorescence intensities of the donor in the pres-
ence (DA) and absence (D) of the acceptor, and τDA and τD the luminescence 
lifetimes, respectively. 
 
FRET-based binding/displacement assays describe whether the unlabelled 
inhibitors are capable of binding to PK by distribution of FRET between the 
fluorophores (fluorescently labelled PK and probe). It has been demonstrated 
that these studies can be efficiently performed in both biochemical as well cell-
based assay formats with different PKs (Kwan et al. 2009; Vaasa et al. 2010; 
Manoharan et al. 2016). However, biological samples may still possess some 
disturbing background autofluorescence which interferes with the signal detec-
tion. Therefore, TR measurement techniques in combination with long-lifetime 
donors luminophores (e.g., lanthanides) are utilized (Soini and Hemmila 1979; 
Li et al. 2008).  
 
 
1.3.3. Time-resolved Förster-type resonant energy transfer 
TR-FRET refers to FRET measurements which are performed in TR format. 
The difference of TR-FRET and the conventional steady-state FRET stems 
from the luminescence properties of the donor luminophore that possess long 
luminescence decay time in case of TR-FRET assays. Introducing a time delay 
(usually 50-150 microseconds) between the initial donor excitation with flash of 




scaled background fluorescence is ceased leading to increased sensitivity and 
precision of the assay (Soini and Hemmila 1979). 
Most commonly used donors in TR-FRET measurements are luminescent 
complexes (e.g., chelates and cryptates) of lanthanide ions. They are widely 
used in various bioanalytical FRET methods (e.g., homogeneous immunoas-
says) for monitoring biological binding events (Lebakken et al. 2009; Hagan 
and Zuchner 2011; Rajendran et al. 2013; Geissler et al. 2014). Furthermore, 
some of the lanthanide complexes are also successfully applied in several com-
mercially available assays for detection of different biomarkers: TRACE®/ 
Kryptor® system of Brahms, HTRF® of CisBio, and Lanthascreen® of 
Invitrogen (Hemmilä and Laitala 2005; Moore et al. 2009). 
Ions of lanthanides (e.g., europium, terbium, samarium, or dysprosium) are 
trivalent cations and they display emission, which is the result of the formally 
forbidden transitions of the f electrons. Because of their low extinction coeffi-
cients (ε ~ 1 M-1cm-1) in bioanalytical measurements lanthanides are usually not 
excited directly but rather through light-absorbing organic heterocycles in 
proximity to the lanthanide ion. These light-harvesting antennas increase 
extinction coefficients of the complex above 10,000 M-1cm-1 (Demchenko 
2015). In addition, these complexes are important for protecting the ion from 
the interactions with the solvent and other possible quenchers of the lumines-
cence in the buffer. Indirect excitation (or antenna effect) occurs through 
organic chelating ligands that after light absorption are excited to the singlet 
state, followed by the non-radiative energy transfer to their triplet state. There-
after, the energy is transferred to the emitting lanthanide ion (Soini and 
Hemmila 1979; Bünzli and Piguet 2005). Lanthanide-chelator complexes 
exhibit luminescence lifetimes in the µs–ms timescale. Moreover, due to the 
structure of the lanthanide complexes and several ground states of lanthanide 
ions, they express very specific (narrow band line-type) luminescence emission 
bands and exhibit large Stokes shifts after excited in the near-UV region 
(Hemmilä and Laitala 2005; Bünzli and Piguet 2005). Hence, a wide selection 
of different acceptor fluorophores (organic dyes, fluorescent proteins, quantum 
dots, etc.) can be applied as FRET acceptors (Hötzer et al. 2012; Geissler et al. 
2014). 
In addition to the TR readout that eliminates background fluorescence, 
another advantage of using lanthanide complexes as FRET donors is the possi-
bility of spectral isolation of lanthanide emission signals and performance of 
dual wavelength detection. This allows the normalization of acceptor emission, 







1.4. Methods for measurement of protein  
phosphorylation and kinase activity in cells 
Measurement of both protein phosphorylation extent and PK activity in cells is 
useful for evaluating the cellular uptake of PK inhibitors and describing bio-
logical activity of the compounds. If the inhibitor is capable for penetrating cell 
plasma membrane and its intracellular localisation is favourable for inhibition 
of activity of target PK, therefore several changes (e.g., phosphorylation of 
substrate peptide/protein, protein production) in cell signalling pathways could 
be detected (Delghandi et al. 2005; Stebbins et al. 2011; van Wandelen et al. 
2013). 
A classical method for identification of phosphorylated proteins in signalling 
pathways involves the incubation of cells with 32PO4 (
32P-ortophosphate). 
During the incubation, the cellular ATP equilibrates with 32P, and the radio-
labelled ATP is thereafter used by PKs for the phosphorylation of their sub-
strates (de Graauw et al. 2006). Subsequently, the phosphorylated proteins are 
separated (e.g., by SDS gel-electrophoresis) and the phosphorylation status of 
the protein is determined using scintillation counting. However, radiolabelled 
methods have many disadvantages, including the short half-life of 32P, personal 
radioactivity risks, and environmental pollution, which has promoted the devel-
opment of numerous non-radiometric assays. 
Immunoblotting is a useful technique for identifying proteins and their phos-
phorylation states, providing an important tool for studying signal transduction 
pathways and activities of PKs in cells. One important requirement for a suc-
cessful immunoblotting assay is that an antibody, either poly- or monoclonal, is 
available for the target protein or in case of phosphorylation, for phosphorylated 
tyrosine, threonine, or serine residues (Kaufmann et al. 2001). In addition, a 
secondary antibody, conjugated with specific enzyme [alkaline phosphatase 
(AP), horseradish peroxidase (HRP)] or a fluorescent dye is needed for visuali-
zation of the separated proteins. 
In order to visualize PK activity and determine cellular inhibitory potency of 
PK inhibitors in living cells (and in real-time), several genetically encoded 
FRET-based biosensors have been created (Nagai et al. 2000; Zhang et al. 
2001; Zaccolo 2004; Friedrich et al. 2010; Prével et al. 2014). Typically a 
FRET-based biosensor consists of a recognition element for the target PK  
(a substrate sequence and binding domain) which is fused to fluorescent 
proteins. Conformational changes in the biosensor report on activity of the 
target PK through changes in FRET efficiency (Zhou et al. 2012; Prével et al. 
2014). 
A-kinase activity reporter (AKAR) and the indicator of CREB activation due 
to phosphorylation (ICAP) are FRET-based biosensors that can be used for the 
determination PKA activity in live cells (Zhang et al. 2001; Zaccolo 2004; 
Friedrich et al. 2010). AKAR is a four-part chimeric protein consisting of cyan 
fluorescent protein, phosphoamino acid binding domain (14-3-3), substrate 




protein. The phosphorylation of kemptide leads to the conformational change of 
the probe, bringing fluorescent proteins to closer proximity which results in 
increase of FRET intensity. Similar principle has been applied for imaging 
CREB activation in live cells, where the ICAP sensor reports phosphorylation 
of the Ser133 residue in the kinase-inducible domain (KID). To monitor CREB 
activation, the KID domain of CREB is fused with CREB interaction domain 
(KIX) of CBP, which specifically recognizes phospho-Ser133. Phosphorylation 
at Ser133 leads to a conformational change and subsequent FRET change. 
PK activity in cells can be also detected with the aid of TR measurements in 
homogeneous cellular kinase assays (Saville et al. 2012; Hermanson et al. 
2012). In this case a suitable PK substrate can be expressed as a fluorescent 
fusion protein and increase of the signal is detected when the lanthanide-
labelled antiphospho-antibody binds to the phosphorylated product, permitting 
energy transfer from the lanthanide label to the acceptor fluorophore. 
Reporter-gene assays, on the other hand, follow a general principle, where 
changes in intracellular signalling pathways (e.g., cAMP concentration changes, 
PKA and CREB activation) are detected via changes in the expression level of a 
particular gene (the reporter-gene) (Jiang et al. 2008). In order to generate a 
reporter-gene assay for a single signalling cascade, a synthetic promoter con-
taining a single type of transcription factor binding site, such as CRE, can be 
constructed (Hill et al. 2001). The transcription of the reporter-gene occurs 
when phosphorylated CREB binds to CRE. In order to measure transcription 
rates, numerous reporter systems have been developed in which production of 
β-galactosidase, green fluorescent protein, firefly luciferase, growth hormone, 





2. AIMS OF THE STUDY 
The aims of the present study proceeded from the requirements of biomedical 
research. A great need remains for small-molecule regulators of the activity of 
PKs in cells and for monitoring systems of PK activity based on synthetic 
organic photoluminescent probes. Most important objectives for the study were 
following: 
 
 Establishment of effect of the structure of adenosine-mimicking fragment 
of bisubstrate ARC-inhibitors on their inhibitory potency towards baso-
philic PKs that possess similar consensus sequence (PKAc, PKBγ, 
ROCK-II). 
 Testing of new ARC-based photoluminescent probes in combination with 
europium-labelled antibodies targeted to the tag of the PK to work out a 
homogeneous binding assay for analysis of a specific PK in biological 
solutions using TR measurement mode of luminescence intensity. 
 Characterisation of the applicability of ARC-based photoluminescent 
probes in biochemical assay formats as well in the complicated biological 
systems (live cells or cell lysates). 
 Adaption of methods that enable monitoring of the phosphorylation of 
CREB in the cell nuclei for ARC-based inhibitors of PKs. 
 Demonstration of ability of ARC-inhibitors to affect the PK-catalysed 
phosphorylation of proteins in living cells. Establishment of the structural 
elements of ARCs that affect their inhibitory potency and cell plasma 




3. MATERIALS AND METHODS 
3.1. Peptide phosphorylation assay for determination of 
activity and inhibition of protein kinases 
The peptide phosphorylation was carried out in 96-well polystyrene plates (40 µl 
reaction volume) thermostated at 30 °C. The reaction mixture contained 50 mM 
Hepes hemisodium salt (pH = 7.5), 10 mM magnesium acetate, 0.2 mg/ml 
bovine serum albumin (BSA), and 5 mM dithiothreitol (DTT). The kinase 
(PKAc or PKBγ), ATP and substrate (5-TAMRA-kemptide or 5-TAMRA-Ahx-
RPRAATF, respectively) were added in various concentrations. 
The phosphorylation reactions were initiated by the addition of ATP. At 
fixed time points, the reaction was terminated by a 7-fold dilution of aliquots (2 µl) 
from the incubation medium with 75 mM aqueous phosphoric acid. Obtained 
mixtures were analysed by thin-layer chromatography (TLC). 
Samples (2 µl) were spotted onto a silica gel TLC plate 5–6 mm apart. The 
plate was dried over a hotplate (100 °C for 10–15 min) and developed with  
1-butanol/pyridine/acetic acid/water (15/10/3/12 by volume). After drying, the 
fluorescence imaging of the plate was performed on a Molecular Imager FX Pro 
Plus (Bio-Rad; ex 532 nm, em 555 nm long-pass filter). The concentration of 
the phosphorylated substrate in the sample was calculated from the ratio of the 
integrated intensity of the substrate’s spot to the sum of the intensities of the 
substrate spot and its phosphorylated product spot. 
The inhibitory potency was determined in the presence of a concentration 
series of inhibitors (three-fold dilutions), and the inhibition curves were fitted to 
a sigmoidal dose–response model to yield IC50 values (corresponding to the 
concentration of the inhibitor decreasing the activity of the enzyme twofold). 
 
 
3.2. Binding/displacement assays in  
time-resolved measurement mode 
All biochemical binding/displacement experiments were performed on black 
low-volume 384-well nonbonding-surface microplates (cat. no. 3676, Corning). 
Experiments were performed in the assay buffer containing 50 mM HEPES 
hemisodium salt (pH = 7.5), 150 mM NaCl, 5 mM DTT, 0.5 mg/ml BSA, and 
0.005 % Tween-20 with final volume of 20 µl. The binding assay was used for 
the determination of the concentration of active PK by titrating PK with ARC-
Lum probe. 3-fold dilutions of PK were made in the assay buffer and the fixed 
concentrations of luminescent probe were added to each well. The microplates 
were incubated for 15 min at 30 °C before each measurement. After incubation, 
the luminescence intensities were measured and the results were analysed with 




















where B is the background signal; M is the luminescence intensity of the 
PK/ARC-Lum complex; Lt is the total concentration of ARC-Lum probe; E0 is 
the nominal concentration of the kinase; KD is the dissociation constant between 
ARC-Lum and PK; and k is the fraction of the active kinase. 
 
The displacement assay was performed by adding the fixed concentration of 
ARC-Lum probe in the complex with PK to the concentration series of the 
competitive compound (3-fold dilutions) in the assay buffer. After 15 min incu-
bation time at 30 °C, the luminescence intensity was measured and the results 
were fitted to a sigmoidal dose-response model with GraphPad prism software 
to obtain IC50-values. Displacement constant Kd values were calculated accord-
ing to equation 2 or equation 3 (Cheng and Prusoff 1973; Nikolovska-Coleska 
et al. 2004). 
For both, the binding and displacement assays, luminescence measurements 
were performed with a PHERAstar platereader (BMG Labtech) using optical 
modules [ex 337 (50) nm, em 675 (50) and 620 (20) nm], [ex 337 (50) nm, em 
590 (50) and 545 (10) nm], or [ex 337 (50) nm, em 630 (40) nm] in the TR fluo-
rescence measurement mode (50 μs delay time and 150 μs acquisition time). 
 
 
3.3. Transient transfection and luciferase assay 
For monitoring the activity of PKA in cell nuclei that leads to the phosphoryla-
tion of CREB at Ser133 resulting in increased luciferase expression and activ-
ity, the cells were transfected with pGAL4-CREB and p(GAL4)5-E1b-Luc 
plasmids by using transfection reagents Lipofectamine2000 (Invitrogen) or 
ExGen500 (Fermentas) according to the instructions from the manufactures. 
After treating the cell cultures with transfection mixtures for 3-4 h, the cells 
were washed with Dulbecco's phosphate-buffered saline (DPBS) and then 
serum-starved for 20–24 h in 0.2 % serum until the performance of the 
experiment. 
One day after the transfection, the growth medium from each well was 
displaced with a fresh medium, free of serum and antibiotics. Thereafter, the 
cells were incubated with different inhibitors at desired concentrations at 37 °C 
and 5 % CO2 for 1 h. Thereafter, forskolin at an appropriate concentration was 
added and the cells were incubated for 3 h. After incubation, the reaction mix-
ture was removed and the cells were washed carefully with DPBS. Thereafter, 
the lysis buffer containing TROPIX Lysis solution (Applied Biosystems) and 
0.5 mM DTT or Cell Lysis Buffer (Invitrogen) with 1x Protease Inhibitor Cocktail, 
1 % Triton-X, and 0.5 mM DTT was added to the cells. The cell lysates were 




For measuring of the activity of luciferase in cell lysates, a Luciferase 
Reporter 1000 Assay System (Promega) or the solution containing 100 μM  
D-luciferin monopotassium salt (Thermo Scientific) in 30 mM tricine buffer  
(pH = 7.8) with 8 mM magnesium acetate and 1.5 mM ATP was used. 
Luciferase activity was assessed by using Labsystems Luminoscan RT 
luminometer (em 560 nm) or PHERAstar platereader with optical module  
[em 515 (30) nm, em 410 (80) nm], respectively. 
 
 
3.4. Immunoblot analyses 
All immunoblot analyses were performed with extracts obtained from the cells 
grown on 12-well plates. The day before the experiment, the cells were serum-
starved in 0.2 % serum for overnight. The cultured cells were treated with dif-
ferent inhibitors for 1 h and with forskolin for 30 min. After that, the cells were 
washed twice with DPBS, harvested in lysis buffer [40 µL, DTT (0.1 M), 
NuPAGE LDS Sample Buffer (1x), and ddH2O], heated to 70 °C for 10 min, 
and sonicated two times for 3 s. Samples were analysed by gradient or 10 % 
SDS polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to 0.45 
µm polyvinylidene difluoride (PVDF) membrane. The blots were blocked with 
TTBS buffer [Tris-HCl (100 mM, pH = 7.4), Tween-20 (0.1 %), NaCl (0.9 %)] 
containing BSA (3 %) for 1 h at room temperature. Thereafter, the blots were 
incubated with primary antibodies, phospho-CREB Ser133 (Santa Cruz) and α-
tubulin (Abcam), overnight at 4 °C in TTBS buffer containing BSA (1 %). After 
overnight incubation, blots were washed with TTBS buffer and incubated for 1 
h at room temperature with AP-conjugated anti-rabbit (AnaSpec) and anti-
mouse (Applied Biosystems) antibodies. After washing with TTBS, the blots 
were equilibrated with AP substrate buffer [Tris-HCl (100 mM, pH = 9.5), NaCl 
(100 mM), MgCl2 (5mM)] and visualized with a NBT (BioChemica) and BCIP 
(Thermo Scientific) substrate mixture. The blots were scanned with CanoScan 





4. RESULTS AND DISCUSSION 
4.1. Characterisation of high-affinity bisubstrate- 
analogue inhibitors of AGC kinases 
The importance of PKs in cell signalling pathways and their involvement in 
various pathological processes has made PK inhibitors into important thera-
peutic agents. In addition, the need for more effective screening assays for dis-
covering PK inhibitors as well for detecting the cellular functioning of PKs has 
increased. Numerous approaches and strategies describe how to target PKs and 
design a potential drug (Sharma et al. 2016). In the present study a structure-
guided design was followed to improve the properties (affinity and selectivity) 
of ARC-based inhibitors towards AGC kinases. This activity was aimed to 
obtain potent compounds for the development of biochemical assays that would 
allow more accurate measurement of the activity of PKs, and screening and 
characterisation of PK inhibitors. 
Previously obtained 3-D structures of ARC/PK co-crystals have served as 
the basis for the development ARCs of the third generation (Figure 1). These 
ARCs incorporate a chiral spacer and two flexible organic linkers. They possess 
nanomolar affinity towards several basophilic PKs (Lavogina et al. 2009). In 
the present study, we aimed to increase the potency of ARC-based inhibitors to 
the subnanomolar region. Therefore, a previously described compound Adc-
Ahx-DLys-Ahx-(DArg)2-NH2 (ARC-1012) was used as the lead compound and 
Adc (adenosine 4’-dehydroxymethyl-4’-carboxylic acid) moiety was substituted 
by different structural fragments (Paper I Table 1). The choice of new frag-
ments was made based on the previously reported co-crystal structures of the 
compounds that bind to the ATP pocket of PKs (Lin et al. 2006; Lavogina et al. 
2009). 
To compare the newly synthesized compounds as inhibitors of PKs, their 
inhibitory potency or affinity towards several PKs (PKAc, PKBγ, and ROCK-II) 
was determined (Paper I Table 1). A TLC-based kinetic method (Viht et al. 
2005) enabling the separation of the substrate peptide 5-TAMRA-Kemptide  
(5-TAMRA-Leu-Arg-Arg-Ala-Ser-Leu-Gly) and its phosphorylated counterpart 
was used for characterisation of inhibitors of PKAc. To assess kinase activity 
and evaluate the inhibitors for PKBγ, a new substrate peptide Arg-Pro-Arg-Ala-
Ala-Thr-Phe was chosen for measurements. The TLC-based method was 
adapted for measurements with the 5-TAMRA derivative of the latter peptide. 
A FA-based binding/displacement assay was applied for determination of 
affinity of the inhibitors towards ROCK-II (Vaasa et al. 2009). 
ARC-1102, the conjugate of AMTH [5-(2-aminopyrimidin-4-yl)thiophene-
2-carboxylic acid] (Table 1) revealed the highest inhibitory potency of the 
tested compounds towards all PKs. Although other compounds showed some 
selectivity towards certain kinases, in general they were still 30–500-fold 





Table 1. Conjugates of 5-(2-aminopyrimidin-4-yl)thiophene-2-carboxylic acid (AMTH) 
 






Thereafter, ARC-1102, the inhibitor with the highest inhibitory potency in the set 
of tested compounds was taken for further structural modifications (Table 1). 
Variation of the chiral spacer as well as the peptide part of the conjugate caused 
similar effect on potency of the compounds (Table 2) as these modifications had 
caused to the inhibitory potency of their Adc-comprising counterparts (Lavogina 
et al. 2009). The conjugates with six D-arginine residues (ARC-664 and  
ARC-663) were 10–25-fold more potent than the compound comprising two  
D-arginine residues (ARC-1102). Moreover, as PKAc equally well tolerates 
several D-amino acids (D-alanine, D-lysine, or D-arginine) in the role of the chiral 
spacer, ARC-664 with D-lysine spacer and ARC-663 with D-alanine spacer 
revealed similar inhibitory potency towards PKAc. However, PKBγ, which 
prefers larger basic amino acids (D-lysine and D-arginine) demonstrated 3.5-fold 
higher potency of ARC-664 compared to ARC-663. Hence, D-alanine as the 
chiral spacer also improved the selectivity of the conjugate towards PKAc. 
 
 
Table 2. Inhibitory potency of conjugates of 5-(2-aminopyrimidin-4-yl)thiophene-2-
carboxylic acid (AMTH) towards PKAcα and PKBγ 
 
Compound 
Inhibition of PKAcα Inhibition of PKBγ 
IC50 (nM) pIC50 ± SE IC50 (nM) pIC50 ± SE 
ARC-1102 82 7.08 ± 0.15 270 6.57 ± 0.14 
ARC-664 5.5 8.26 ± 0.27 12 7.92 ± 0.30 
ARC-663 4.9 8.31 ± 0.23 42 7.38 ± 0.19 
Standard error (SE; 95 % confidence interval) 
1000 µM ATP (Km = 20 µM) was used in kinetic assay of PKAcα and 100 µM ATP  
(Km = 100 µM) was used in kinetic assay of PKBγ. 
 
 
The compounds comprising synthetic non-natural fragments and D-arginine 
residues are expected to be resistant to enzymatic degradation (Elmquist and 
Langel 2003; Enkvist et al. 2006) and thus have great potential for application 




compounds gives the opportunity and advantages to apply them for construction 
of photoluminescent probes that could be used in binding/displacement assays 
for the measurement of concentration of PKs and screening of inhibitors of PKs. 
Because the lowest inhibitor Kd value that can be resolved in an FA-based 
binding assay is approximately equal to the KD value of the probe, inhibitors 
with low-nanomolar affinity can be used for characterisation of non-labelled 
inhibitors with affinities in whole nanomolar and micromolar range (Huang 
2003; Vaasa et al. 2009). Moreover, as the selectivity panel of PK inhibition 
showed that ARC-664 efficiently inhibited most of the tested basophilic 
kinases, a single ARC-based probe can be used for testing of several PKs. 
Although homogeneous, rapid, and inexpensive binding-based bioanalysis 
methods have great potential as tools for HTS of small-molecule inhibitors, the 
“classical” kinetic inhibition assays maintain their importance as they give the 
direct information about the PK-catalysed phosphorylation reactions. However, 
Vaasa et al. have demonstrated good linear dependency (R2 = 0.95) between the 
inhibitory potency (IC50 as measured by the TLC-based kinetic inhibition assay) 
and affinity (Kd as determined in FA assay with an ARC-based fluorescent 
probe) of various inhibitors of PKAc (Vaasa et al. 2009). In the course of the 
present study, the linear dependency (R2 = 0.97) was also shown between the 
inhibitory potency and affinity of different ARC-inhibitors and H89 for PKBγ 
(Figure 3 unpublished data). Therefore, binding/displacement assays can be 
efficiently used for characterising PK inhibitors and support the further usage of 
those tested compounds as inhibitors or regulators of protein phosphorylation 




Figure 3. Correlation between the inhibitory potency (pIC50 TLC, measured with TLC-
based kinetic inhibition assay) and affinity (pIC50 FA, measured with the FA-based 
binding/displacement assay) for various inhibitors towards PKBγ. The data set contains 
H89 (well-characterised commercially available ATP-competitive inhibitor), ARC-902 
(II generation Adc-containing ARC-based inhibitor) (Enkvist et al. 2006), ARC-663 
and ARC-664 (AMTH-containing ARC-based inhibitors) (Paper I). Structures of three 




4.2. Development and application of bioassays based on 
photoluminescent probes 
4.2.1. Discovery of ARC-Lum probes 
Many photoluminescence-based assays have been disclosed for determination 
of PKs as specific biomarkers or for screening and characterisation of small-
molecule inhibitors (Lebakken et al. 2007; Kwan et al. 2009; Uri et al. 2010; 
Morris 2013). The development of biochemical assays based on the application 
of ARC-based photoluminescent probes has moved along together with the 
improvement of affinity of ARCs towards PKs. ARC-Fluo probes have been 
successfully used in FA-based assays for determination of concentration of 
different basophilic PKs or characterisation of PK inhibitors possessing affinity 
in micromolar and nanomolar range (Vaasa et al. 2009; Uri et al. 2010; 
Lavogina et al. 2012). ARC-Fluo probes have been also successfully applied for 
FRET-based assays in pair with PKs that were either chemically labelled with 
fluorescent dyes or expressed as fusions with a fluorescent protein (Vaasa et al. 
2010; Manoharan et al. 2016). Moreover, labelling of ARCs with lanthanide 
(e.g., terbium) chelates or cryptates resulted in photoluminescent probes, whose 
emission decay time is in the range of 100–2000 μs, which is suitable for the TR 
measurement format (Uri et al. 2010). 
An europium chelate-based binding assay for PKs using TR-FRET meas-
urement format has been described (Lebakken et al. 2009). The assay works 
with recombinantly tagged kinases and requires the application of antibodies 
that bind to the tag. A drawback of the assay is the usage of fluorescently 
labelled ATP-competitive kinase inhibitors as the tracers (fluorescent probes), 
thus, the assay is suitable for characterisation of the compounds that bind to 
ATP-binding site (or to an allosteric site that changes the conformation of the 
ATP site). 
An advantage of ARC-probes in binding/displacement assays is their bisub-
strate nature that makes possible their application for characterisation of inhib-
itors that are targeting binding sites of both substrates of the PK (Vaasa et al. 
2009; Lavogina et al. 2010b). In order to analyse PKs in complicated biological 
samples a TR-FRET-based three-component assay system with the application 
of ARC-probes and anti-tag antibodies labelled with organic chromophore 
antenna-sensitized europium cryptates was taken under study (Figure 4). 
For the development of a TR luminescence-based bioassay, new high-
affinity ARC-inhibitors comprising AMTH moiety were used (Table 1). 
Substituting the chiral spacer D-alanine in ARC-663 with D-arginine gave the 
compound ARC-668 [AMTH-Ahx-DArg-Ahx-(DArg)6-DLys-NH2]. ARC-668 
was labelled at D-lysine residue with the fluorescent dye Alexa Fluor 647, 
leading to the labelled compound ARC-1063 (Paper II Figure 1B). The latter 
compound (FRET acceptor) was used for the development of a homogeneous 
three-component analysis method, using it together with 6His-tagged 




(FRET donor) (Figure 4). In case of simultaneous association of both europium-
labelled antibody and Alexa Fluor 647-labelled ARC with the kinase, emission 
signal with long decay time was awaited at 675 (50) nm upon pulse-excitation 




Figure 4. Schematic presentation of a homogeneous TR-FRET-based protein kinase 
(PK) assay with the application of Alexa Fluor 647-labelled ARC-probe (FL) and euro-
pium-labelled antibody (Eu). Simultaneous association of europium-labelled antibody 
and fluorescently-labelled ARC-probe with the PK leads to the formation of triple com-
plex and intermolecular FRET. After pulse-excitation of the formed complex at 337 
(50) nm, acceptor’s (FL) emission signal intensity with long decay time increases at 675 
(50) nm, while donor’s (Eu) emission signal intensity decreases at 620 (20) nm. 
 
 
However, we discovered a strong luminescence signal [measurements per-
formed with 50 μs delay time after pulse-excitation at 337 (50) nm] if ARC-
1063 was titrated with PKBγ, without the presence of the europium-labelled 
antibody (Figure 5). 
 
 
Figure 5. Schematic presentation of a homogeneous ARC-based assay for determina-
tion of protein kinases (PKs). Upon pulse-excitation at 337 (50) nm of free Alexa Fluor-
647 labelled ARC-Lum probe (FL) a short-lived fluorescence signal of acceptor dye is 
detected at 675 (50) nm. Binding of probe with PK leads to the intramolecular FRET 
after pulse-excitation at 337 (50) nm and photoluminescence with microsecond-scale 





Closer examination of this phenomenon showed that the measured signal was 
directly proportional to the concentration of the complex of ARC-1063 and 
PKBγ and the displacement of ARC-1063 from the complex by competitive 
inhibitors decreased the luminescence signal in the concentration-dependent 
manner. Novel organic protein binding-responsive long life-time 
photoluminescent probes (ARC-Lum probes) were discovered. 
 
 
4.2.2. Photoluminescence signal of ARC-Lum probes 
Upon binding to a PK and excitation with a pulse of near-UV radiation ARC-
Lum probes produce long lifetime (τ = 19–266 µs) photoluminescence signal, 
whereas free probe gives negligible long-lifetime emission signal (Figure 5). 
ARC-Lum probes are divided into two categories: ARC-Lum(-) and ARC-
Lum(Fluo) probes, where the latter compounds are fluorescent dye labelled 
counterparts of the corresponding ARC-Lum(-) probes. 
During these studies we observed that ARC-Lum(-) probes possess weak 
photoluminescence (phosphorescence) signal at 500–650 nm in complex with a 
PK, which is more than 1000-fold weaker compared to the luminescence of the 
respective ARC-Lum(Fluo) probes. This effect could be explained with the 
intramolecular FRET between the thiophene-comprising fragment (donor phos-
phor, D) and conjugated fluorescent dye (acceptor fluorophore, A) of an  
ARC-Lum(Fluo) probe (Paper II Figure 1D). The thiophene-comprising 
fragment has an absorption maximum at 340 nm. Flash-excitation of the 
thiophene-comprising fragment at 337 (50) nm while bound to the active site of 
the PK leads to the excited singlet state S(D)1*, followed by ISC to the excited 
triplet state T(D)1* of the fragment. Thereafter, FRET from donor phosphor 
T(D)1* to the singlet state of the acceptor fluorophore S(A)1 takes place, which 
leads to the excited singlet state of the acceptor S(A)1*. Due to the forbidden 
energy transfer from T(D)1* to fluorophore S(A)1, slow emission of light from 
the excited fluorophore occurs. 
Luminescence signal is largely intensified through efficient energy transfer 
and is dependent on the quantum yield and molar absorption coefficient of the 
fluorescent dye and spectral overlap of the donor phosphorescence emission 
spectrum with the absorption spectrum of acceptor fluorescent dye. Here we 
demonstrated that fluorescent dyes (e.g., HilyteFluor 488, TAMRA, Alexa 
Fluor 647, PromoFluor-647) with strong absorption in the wavelength range of 
500–650 nm could be used as effective luminescence-sensitizing acceptors 
(Paper II Supplementary Figures 3, 4A, and 5A). Additionally, it was deter-
mined that the acceptor-mediated amplification of the luminescence signal of 
the donor also takes place intermolecularly. PromoFluor-647-labelled PKAc 
was used together with different ARC-Lum(-) probes and energy transfer was 
detected when donor phosphor moiety of ARC-Lum(-) probe and the 
PromoFluor-647 fluorescent label of the kinase were in close proximity due to 




The formation of the PK-induced luminescence signal was also demon-
strated by changing the sulfur atom in the conjugates with heavier selenium 
atom. Selenium atom in the aromatic system increases the probability of the 
energy transfer to the triplet state after photon absorption and the rate of triplet 
to singlet energy transfer (Kuijt et al. 2003), resulting in a higher intensity of 
the emitted light and its shorter lifetime (Paper II Table 1). Selenophene-com-
prising conjugates of ARC-Lum(-) probes gave a 30- to 100-fold stronger phos-
phorescence signal compared to the thiophene-comprising analogue, pointing to 
the positive heavy-atom effect. Moreover, the phosphorescence signal was 
strong enough to be used for the measurement of the concentration of the 
probe/PK complex. However, it was still 20- to 100-fold weaker than lumines-
cence intensity of the corresponding ARC-Lum(Fluo) probes. No long lifetime 
luminescence signal was detected for adenosine-comprising ARCs labelled with 
fluorescent dye. 
ARC-Lum probes gave a long-lifetime luminescence signal with all the 
tested PKs of the AGC group, whereas different PKs complexed with ARC-
Lum probes led to considerable differences in the intensities and lifetimes of 
emitted light (Paper II Figure 2A and B, Table 1). These differences may come 
from the structure of the active centre of PKs, which behave as a binding, 
fixing, and protecting framework for ARC-Lum probes, and higher the 
rigidness of the binary complexes, the greater the protection of the probe from 
quenching effect of dissolved molecular oxygen and the buffer components. 
 
 
4.2.3. Characterisation of protein kinases and their  
inhibitors in biochemical assays 
The great value that ARC-Lum probes hold due to their binding-responsive 
photoluminescence properties is that they could be effectively used for the 
determination of activity of basophilic PKs, characterisation of inhibitors of 
PKs, and as cAMP sensors in biochemical as well in biological assay systems. 
The measurements are performed with a microsecond-scale time delay after 
pulse-excitation of the probe. Therefore, the measured signal is free from the 
nanosecond-scaled background fluorescence of organic compounds and auto-
fluorescence of cells. Moreover, as ARC-based bisubstrate inhibitors efficiently 
bind only to the active form(s) of PKs, ARC-Lum probes can be used for meas-
uring the concentration of the active form of the kinase in the sample. 
Binding/displacement assays based on the use of ARC-Lum probes are simple, 
quick, and do not need any additional reagents (e.g., substrates or antibodies). In 
addition to TR measurement of luminescence, ARC-Lum(Fluo) probes can be 
in parallel applied for FA- or FI-based steady-state measurements. 
The affinity of the probe towards PKs (KD) or the activity (active fraction) of 
PKs (k) can be determined by performing titration of the ARC-Lum probe with 
the PK (Paper II Figure 2A, B) and fitting the data to the equation 8, similarly 




as free ARC-Lum probe does not give long-lifetime photoluminesence signal, it 
was possible to perform the titration of the fixed concentration of protein with 
varying concentration of the probe (Paper II Supplementary Figure 5A). The 
usability of both titration variants was confirmed by comparable KD values.  
The ARC-Lum-based displacement assay can be used for characterisation of 
inhibitors for several PKs, like PKAc, PKBγ, ROCK-II. The intensity of PK-
induced long-lifetime photoluminescence signal was reduced by various ATP-
competitive, protein substrate-competitive, or bisubstrate inhibitors. The 
obtained displacement constant (Kd) values determined with the ARC-Lum-
based displacement assay were in good agreement with the inhibition constant 
(Ki) values determined using the TLC-based kinetic inhibition assay (R
2 = 0.92; 




Figure 6. Displacement of ARC-Lum(Fluo) probes from the complex with PKs by 
various inhibitors. (A) Correlation between the values of inhibition constant (Ki) 
measured in TLC kinetic inhibition assay and the values of displacement constant (Kd) 
determined in displacement assay with the probe ARC-1063 for various PKAc inhibi-
tors. (B) Displacement of fluorescent probe ARC-1063 [at the concentration of 54 nM 
(■), 18 nM (▲), 6 nM (▼), or 2 nM (♦)] from its complex with PKAc (1 nM) by ARC-902. 
 
 
The absence of long-lifetime photoluminescence signal of free ARC-Lum probe 
gives the opportunity to use the probe at relatively high concentration in the 
displacement assays. Therefore, if [L] >> KD, the results of the measurements do 
not depend on the concentration of active PK and the Kd values for competing 
inhibitor can be calculated from displacement curves (Figure 6B) according to 
the Cheng-Prusoff equation (equation 2) (Cheng and Prusoff 1973). Further-
more, high concentration of the probe allows determination of affinities for 
highly potent compounds by shifting their displacement curves away from the 
tight-binding region (Copeland 2005). Additionally, it is possible to apply a 
single ARC-Lum probe for experiments with PKs possessing different binding 




centration of the probe ensures that sufficient fraction of the kinase is still 
bound to the probe. 
 
 
4.2.4. Characterisation of protein kinase activity  
in live cells and cell lysates 
Methods enabling the monitoring of activity of PKs in complicated biological 
solutions, such as blood serum, cell lysates, tissue extracts, and living cells, 
have great value for biological research. ARC-Lum probes have the potential 
for becoming useful tools in this field of study, as they do not need fluores-
cently labelled target proteins for monitoring changes in activity of PKs in 
native biological systems. 
In the present study human embryonic kidney cells (HEK293) possessing 
native expression level of PKA were incubated with solutions of thiopehene- or 
selenophene-comprising ARC-Lum(Fluo) probes (c = 10 μM). After removal of 
excess of the probe, intracellular localisation of the probe was followed with a 
fluorescence microscope (Figure 7). The localisation of the ARC-Lum(Fluo) 
probe was similar to that of ARC-Fluo probes (Vaasa et al. 2010). Fluorescently 
labelled ARC-Lum probes efficiently penetrated the cell plasma membrane and 
located into the cytoplasm and nucleus of the cell. Similarly to ARC-Fluo 
probes, ARC-Lum(Fluo) probes showed tendency to concentrate in nuclear 




Figure 7. Cellular uptake and localisation of ARC-1139 [selenophene-containing ARC-
Lum(Fluo) probe] in HEK293 cells. HEK293 cells were incubated with 10 µM ARC-
1139 at 37 °C for 1 h. 
 
Activation of PKA by forskolin (the activator of AC) in HEK293 cells led to an 
increased level of free catalytic subunit PKAc whose association with ARC-




signal (Figure 8A, B). Furthermore, even bigger effect was demonstrated in 
case of Chinese hamster ovary cells, C9H6, that are recombinantly 
overexpressing both subunits of PKA (Figure 8A). Increased long-lifetime 
luminescence intensity was also achieved through activation of β-adrenergic 
receptors natively expressed in HEK293 cells with the agonist isoproterenol 
(Figure 8B). A cell-permeable ATP-competitive PKAc inhibitor H89 reversed 
the effect of both compounds (Figure 8A, B). The obtained results point to 
ARC-Lum probes as promising sensors for real-time monitoring of cAMP con-




Figure 8. Measurement of long-lifetime luminescence of ARC-Lum(Fluo) probes in 
biological systems. Real-time monitoring of PKA activity in HEK293 cells (A: ■; B) 
and C9H6 (A: ●) cells using intracellular ARC-1139. Long-lifetime luminescence of 
cells on the bottom of the wells of a microtiter plate was detected with a PHERAstar 
platereader (λex = 337 (50) nm, λem = 675 (50) nm, delay time = 50 μs). Time points of 
addition of forskolin (FRSK, 25 µM; A: ■, ●), isoproterenol (Iso, 10 µM; B: ■, ▲), and 
H89 (100 µM; A: ■, ●; B: ■, ▼) are marked with arrows. 
 
 
Lower concentrations of ARC-Lum probes were needed for monitoring the PK 
activity in cells after their lysis (Paper II Figure 5D). Forskolin increased the 
long-lifetime luminescence signal in a concentration-dependent manner com-
pared to nonactivated cells, whereas specific PKA inhibitor PKI reduced the 
signal by displacing ARC-Lum probe from its complex with the PKAc. 
ARC-Lum probes can be successfully used for real-time monitoring of 
activity of PKs in cells possessing the native expression level of PKs with no 
need for recombinant expression of fusions with fluorescent proteins. ARC-
Lum probes have been efficiently adapted for determination of the concentra-
tion of a putative biomarker extra-cellular PKA (ECPKA) in patients’ blood 
plasma samples and for mapping activity of PKs in live cells with time-gated 




4.3. Biological effect of bisubstrate-analogue  
inhibitors in living cells 
We have shown that ARC-inhibitors possess high affinity towards several PKs 
(PKAc, PKBγ, ROCK-II, etc.) and they are chemically and biologically stable. 
ARCs labelled with fluorescent dyes [ARC-Fluo and ARC-Lum(Fluo) probes] 
are capable for penetrating cell plasma membrane and interacting with PKs in 
cellular milieu. Therefore, ARC-probes are useful tools for biochemical and 
cell-based assays to determine activity of PKs and characterise inhibitors of PKs 
(Vaasa et al. 2009; Vaasa et al. 2010; Kasari et al. 2012; Vaasa et al. 2012). 
Although ARC/PK co-crystal studies and biochemical inhibition assays have 
demonstrated that ARCs inhibit PK-catalysed phosphorylation reactions by the 
bisubstrate mechanism, the capability of ARCs to regulate phosphorylation of 
proteins in living cells has not been well characterised. Overall, only a limited 
number of publications describe the potency of bisubstrate inhibitors to affect 
the phosphorylation of proteins in living cells (Räägel et al. 2008; Stebbins et 
al. 2011; Lamba and Ghosh 2012; van Wandelen et al. 2013; Gower et al. 
2014) and therefore it was essential to take this potential of ARCs under investi-
gation. 
Several important cellular signalling cascades are initiated by the activation 
of PKA (Tasken 2004; Turnham and Scott 2016). In this study, the effect of 
ARCs on the PKA-catalysed phosphorylation of CREB was studied in 
mammalian cells. CREB (MW = 43 kDa) is a transcription factor that induces 
gene transcription after being phosphorylated at Ser133 by PKA or other PKs. 
Moreover, in case of the forskolin-activated pathway, PKA is the main CREB-
phosphorylating PK (Johannessen et al. 2004a; Delghandi et al. 2005). There-
fore, the reaction of CREB phosphorylation is a good target for monitoring the 
inhibitory efficiency of ARC-inhibitors in living cells. 
A series of ARCs with varying PK-binding and plasma membrane-pene-
trating properties was tested in cells as regulators of protein phosphorylation. In 
order to test the cellular PK inhibitory potency of structurally diverse ARCs, 
several new structural modifications were introduced into previously biochemi-
cally characterised compounds (Table 3). In addition to the effect of structural 
modification of the adenosine-mimicking moiety (Adc-, AMTH-, and dPurp-
moiety) of ARCs, the effect of hydrophobic groups attached to the lysine 












Table 3. Structures and codes of the tested compounds; Kd values determined with the 
displacement assay 
 




Adc-Ahx-(DArg)6-DLys-NH2 ARC-904 0.4 
Adc-Ahx-(DArg)6-DLys(Myr)-NH2 ARC-1222 3.7 
Adc-Ahx-(DArg)6-DLys(Hex)-NH2 ARC-1171 0.2 
Adc-Ahx-(DArg)6-DLys(C(O)(CH2)2-P
+(Ph)3)-NH2 ARC-1172 0.1 
dPurp-C(O)(CH2)7C(O)-(DArg)6-DLys(Myr)- NH2 ARC-1412 0.1 
AMTH-Ahx-Ala-(DArg)6-DLys(Myr)-Gly ARC-1143 2.3 
AMTH-Ahx-(DArg)-Ahx-(DArg)6-DLys(Myr)-NH2 ARC-681 1.8 
 
 
HPLC-based analysis of intracellular concentration of labelled and unlabelled 
ARCs in cells has demonstrated an intense uptake of the conjugates (up to  
10-fold augmentation of the concentration of some ARCs in cells compared to 
their concentration in incubation solution) (Hedi Sinijärv, unpublished data). 
Meanwhile, myristoylated ARCs were taken up by the cells even more 
intensively (Hedi Sinijärv, unpublished data). This result, together with the 
great structural stability of ARCs comprising only D-amino acid residues in 
cellular milieu (Enkvist et al. 2006), pointed to the applicability of ARCs for 
regulation of intracellular protein phosphorylation balances. 
The biochemical affinity (Kd) of each compound towards PKAc was deter-
mined with ARC-Lum-based assay using the selenophene-comprising probe 
ARC-1139 (Paper II Figure 1). The affinities of the compounds towards PKAc 
were in nanomolar or subnanomolar range (Table 3). Although myristoylation 
decreased the affinity of the conjugates, the acylated ARCs still bound to PKAc 
three- to 100-fold more tightly than H89. The latter compound is a well-char-
acterised commercially available small-molecule ATP-competitive inhibitor of 
PKAc and other PKs of the AGC group (MSK1, ROCK-II, etc.), which has 
been used as a reference compound for evaluating cellular inhibition of PKs 
(Davies et al. 2000). It has been shown that H89 at 10 µM concentration 
abrogates forskolin-induced phosphorylation of CREB (Delghandi et al. 2005).  
The biochemically characterised ARCs were further tested in mammalian 




PKAc. The effect of inhibitors on CREB-dependent transcription and CREB 
phosphorylation was monitored with both a luciferase reporter assay and an 
immunoblot-based protein phosphorylation assay. Luciferase reporter assay is a 
relatively simple, rapid, and sensitive technique for studying gene expression at 
the transcriptional level. It has been used for the determination of the inhibition 
effects in cell signalling pathways (Delghandi et al. 2005; Mano et al. 2014). 
However, it has been noticed that some PK inhibitors (e.g., H89) affect lucif-
erase-mediated bioluminescence directly (Herbst et al. 2009; Dranchak et al. 
2013), therefore determination of CREB phosphorylation with phospho-specific 
antibodies was also performed. The obtained inhibition profiles from both 
methods were similar and the dependency between pIC50 values from the lucif-
erase assay and the immunoblot analysis (R2 = 0.87; Paper III Figure 7) 
demonstrates that both of the methods can be used for assessing the inhibitory 
potential of compounds on PKAc activity in living cells.  
All tested myristoylated conjugates (ARC-1222, ARC-1143, ARC-1412, and 
ARC-681) caused dose-dependent decrease in CREB-mediated luciferase activ-
ity and CREB phosphorylation (Paper III, Figure 4, 6). Some inhibitors (e.g., 
ARC-681) led to a substantial decrease in the activity of CREB at 5, 10, and 20 
μM concentration and to relatively weak inhibition at 1 μM concentration. This 
observation is in accordance with the results of earlier studies using ARC-Fluo 
probes in cell cultures, which demonstrated that a “critical” threshold of the 
ARC-Fluo concentration had to be overcome in order to obtain effective inter-
nalization of conjugates into cells (Vaasa et al. 2010). The same phenomenon, 
endocytosis-independent concentration threshold-sensitive transport mechanism 
via localised regions of the plasma membrane has also been described for argi-
nine-rich transport peptides (Duchardt et al. 2007; Brock 2014). 
Because of the high intracellular concentration of ATP (1–5 mM) (Beis and 
Newsholme 1975; Ando et al. 2012), ATP-competitive inhibitors H89 and 
ARCs reveal cellular IC50 values in the low micromolar range. The comparison 
of IC50 values (Table 4) with the Kd values from the biochemical measurements 
(Table 3) shows that myristoylated compounds with lower Kd values (ARC-
1412, ARC-681) act more effectively in living cells than compounds possessing 
higher Kd values (ARC-1222 and ARC-1143). However, another set of com-
pounds (ARC-904, ARC-1711, and ARC-1172) did not have a significant influ-
ence on the activity of CREB (Paper III Figure 2B), although their affinity 
towards PKAc was generally higher than that of the myristoylated conjugates. 
H89, on the other hand, has good inhibitory potency in cells, although its bio-
chemical Kd value is higher than these of ARCs. Therefore, more efficient inhi-
bition of the cAMP/PKA pathway by H89 (compared to ARCs) may be (par-
tially) due to its better internalization into cells and localisation to the cell 






Table 4. IC50 values for the effect of inhibitors on the activity of PKAc in Chinese 
hamster ovary cells (CHO-K1) analysed by luciferase reporter assay and phospho-
CREB immunoblotting assay 
 
Compound 
Luciferase assay Immunoblot assay 
IC50 (µM) pIC50 ± SE IC50 (µM) pIC50 ± SE 
H89 2.6 5.59 ± 0.09 6.4 5.19 ± 0.06 
ARC-1222 4.2 5.38 ± 0.19 5.8 5.23 ± 0.41 
ARC-1412 1.9 5.73 ± 0.17 4.7 5.33 ± 0.49 
ARC-1143 18 4.75 ± 0.21 13 4.87 ± 0.45 
ARC-681 1.4 5.85 ± 0.18 2.8 5.56 ± 0.46 
 
Standard error (SE; 95 % confidence interval) 
 
 
A cascade of biological and physical processes, including final co-localisation 
of CREB and PKAc, spatially and temporally regulates PKAc-mediated phos-
phorylation of CREB. Our previous fluorescence microscopy studies with 
ARCs labelled with fluorescent dyes have revealed that these compounds have a 
tendency to concentrate into nuclear subdomains, nucleoli (Figure 7), whereas 
CREB proteins are almost fully excluded from these nuclear subdomains 
(Uhlen et al. 2010). Thus, different intra-nuclear compartmentalization of 
CREB proteins (and PKAc) on one hand and ARCs on the other hand may be a 
cause of lower than expected intracellular inhibitory potency of ARCs. How-
ever, the improvement of cellular inhibitory potency of ARCs could be 
achieved with a simple structural modification of the conjugates, N-myristoy-
lation. These results point to the importance of further research on structural 
modifications of ARCs that could lead to their better intracellular targeting and 
improved availability by nuclear PKs for regulating the phosphorylation of 
functionally important proteins. Moreover, those improved compounds could be 
useful for the construction of photoluminescent probes for monitoring and map-






This thesis describes the development and characterisation of high-affinity 
bisubstrate-analogue inhibitors (ARC-inhibitors) with improved properties for 
further applications in biochemical and biomedical research for determining the 
activity of PKs, screening and characterising of PK inhibitors, and for 
regulating protein phosphorylation balances in signalling pathways of cells. The 
main results of the present research can be summarized as follows: 
 Several heteroaromatic structures were used as adenosine mimics of 
ARCs to produce bisubstrate inhibitors for basophilic PKs with up to 
picomolar potency. 
 A conjugate with thiophene-containing moiety [AMTH-Ahx-DLys-Ahx-
(DArg)2-NH2] was shown to be a more potent inhibitor than its adenosine 
counterpart towards all three tested PKs (PKAc, PKBγ, ROCK-II). 
 The inhibitory potency of AMTH-Ahx-DLys-Ahx-(DArg)2-NH2 was 
increased to subnanomolar region by increasing the number of D-arginine 
residues in the peptidic fragment. 
 Long-lived emission of a thiophene-comprising fluorescently labelled 
ARC in complex with PKBγ was discovered in the course of develop-
ment of a TR-FRET assay based on the application of organic chromo-
phore antenna-sensitized lanthanide cryptates.  
 Binding of a thiophene- or a selenophene-comprising heteroaromatic 
moiety (luminescence donor) to the purine-binding pocket of PK induced 
long lifetime photoluminescence (phosphorescence) signal that was 
largely intensified through efficient energy transfer to a fluorescent dye 
present in close proximity to the luminescence donor. 
 The developed ARC-Lum probes were successfully used for determina-
tion of the concentration of active PKs as well for characterising various 
PK inhibitors in biochemical assays. 
 ARC-Lum probes were used for real-time monitoring of activity of PKs 
in cells possessing native expression level of PKs with no need for 
recombinant expression of PK fusions with fluorescent proteins. 
 ARC-inhibitors with varying PK-binding and plasma membrane-pene-
trating properties were tested as regulators of protein phosphorylation in 
living cells through the effect on cAMP/PKA/CREB signalling pathway. 
 Low micromolar extracellular concentration of N-myristoylated ARCs 
was shown to be capable for reducing the activity of the transcription 
factor CREB through inhibition of PKAc. The cellular inhibitory potency 
of the compounds was depended on both their cell-penetration capability 






6. SUMMARY IN ESTONIAN 
Proteiinkinaaside aktiivsust registreerivate  
fotoluminestsents-sondide ja rakusiseste  
inhibiitorite arendamine 
Proteiinkinaasid (PK-d) on olulised valkude aktiivsust reguleerivad ensüümid, 
katalüüsides nende fosforüülimist ning olles seega oluliseks lüliks rakusisestes 
signaalülekande radades. Hälbeid PK-de normaalses funktsioneerimises, mis on 
enamasti tingitud nende liigsest aktiivsusest, üleekspressioonist või geenimutat-
sioonidest, on seotud mitmete haigustega, nagu vähkkasvajad, diabeet, südame-
veresoonkonna haigused. Sellest tulenevalt on PK-dest saanud olulised ravimi-
arenduse sihtmärgid ning üle 30 PK inhibiitori on jõudnud vähiravimina kasu-
tusele (Rask-Andersen et al. 2014; Wu et al. 2015). Lisaks ravimiarendusele on 
toimunud erinevate biokeemiliste analüüsimeetodite arendamine nii uute efek-
tiivsete ravimikandidaatide võimalikult kiireks väljatöötamiseks, PK-de toime-
mehhanismide ja signaalradade uurimiseks kui ka PK-de kui haiguste bio-
markerite tuvastamiseks. 
Käesoleva töö eesmärgiks oli uudsete kõrge afiinsusega bisubstraatsete 
ARC-inhibiitorite kasutatavuse selgitamine biokeemilistes ja bioloogilistes 
(elavad rakud ja nende lüsaadid) proovides PK-de aktiivsuse määramiseks ning 
erinevate inhibiitorite iseloomustamiseks. Lisaks uuriti nende ühendite rakenda-
tavust PK-de signaalradade uurimiseks ning kinaaside aktiivsuse reguleeri-
miseks. 
Töö käigus iseloomustati mitmeid erineva struktuuriga ARC-inhibiitoreid, et 
tuvastada olulised ATP sidumistaskusse seostumist mõjutavad struktuuri-
fragmendid, mis lubaksid arendada pikomolaarse afiinsusega selektiivseid 
inhibiitoreid basofiilisete PK-de jaoks. Kõige suurema inhibeerimisvõimega 
ühendiks kolme analüüsitud PK-i (PKAc, PKBγ, ROCK-II) suhtes osutus 
konjugaat, mille ATP sidumistaskusse seonduvaks osaks oli tiofeeni fragmenti 
sisaldav aromaatne struktuur. Järgnevalt optimeeriti linkerit ning PK substraat-
valgu sidumistaskusse seonduvat osa, mille tulemusel saadi ARC-inhibiitor, 
mida rakendati Försteri energia resonantsülekandel (FRET) põhineva meetodi 
arendamiseks PK-de aktiivsuse määramiseks ning inhibiitorite iseloomusta-
miseks nii biokeemilistes kui ka bioloogilistes proovides. 
Meetodi väljatöötamiseks võeti aluseks kolmekomponendiline süsteem, mis 
koosnes sihtmärk kinaasist, orgaanilise kromofoorantenniga sensibiliseeritud 
lantaniidi kelaadiga märgistatud antikehast (FRET-doonor) ning fluorestsents-
märgisega ARC-inhibiitorist (FRET-aktseptor). Lantaniidi kelaatide kui pika 
luminestsentsi elueaga ühendite kasutamine võimaldas teostada viivitusega 
FRET signaali mõõtmist, mis omakorda aitas kaasa uudsete tiofeeni sisaldavate 
ARC-inhibiitorite optiliste omaduste kirjeldamisele ning nendel põhinevate 
ARC-Lum-sondide avastamisele. Töö käigus tuvastati, et uute ühendite seostu-
misel PK-dega ning selle kompleksi ergastamisel kiirgusega lähis-UV alas 




(20–250 μs) valgust. Seega kasutades luminestsentsi viivitusega mõõtmis-
tehnikaid on võimalik efektiivselt hinnata PK-de aktiivust, iseloomustada 
erinevaid inhibiitoriteid ning uurida huvipakkuvaid protsesse reaalajas nii 
geneetiliselt muundamata rakkudes kui ka teistes keerulistes bioloogilistes 
proovides. 
ARC-sondide abil on võimalik määrata aktiivse PK osakaalu lahuses või 
jälgida PK kontsentratsiooni muutusi bioloogilistes süsteemides sõltuvalt 
erinevate inhibeerivate või aktiveerivate ühendite toimest. ARC-de inhibee-
rimisvõime PK-de suhtes ning nende mõju rakusisestele signaalradadele oli 
varem kirjeldamata. Selle uurimiseks kasutati nii varem sünteesitud ARC-
inhibiitoreid kui ka antud töö käigus arendatud ühendeid, mis erinesid eelne-
vatest nii inhibeerimisomaduste kui ka rakkude plasmamembraani läbimise 
võime poolest. Töös uuriti nende ainete mõju cAMP/PKA/CREB signaalrajale. 
Selgus, et kuigi oligoarginiini sisaldavad ARC-d on võimelised läbima raku 
plasmamembraani, siis sihtmärkvalguni (PKAc) jõudmiseks ja inhibeeriva 
toime avaldumiseks on vajalik ühendite struktuuri edasine suunatud modifit-
seerimine. Ühendid, mille struktuuri oli lisatud hüdrofoobne müristiinhappe 
jääk, olid võimelised rakkudes inhibeerima PKAc-d ning vähendama sellega 
transkriptsioonifaktor CREB-i aktiivsust. Sealjuures oli nende ainete inhibeeriv 
efekt sõltuv ainete biokeemilisest afiinsusest PKAc suhtes.  
Saadud tulemused on aluseks uute inhibiitorite konstrueerimisele, mis 
võimaldavad PK-de aktiivsuse suunatud reguleerimist rakkudes, ning bio-







Ando T., Imamura H., Suzuki R., Aizaki H., Watanabe T., Wakita T., Suzuki T. (2012) 
Visualization and measurement of ATP levels in living cells replicating hepatitis C 
virus genome RNA. PLoS Pathog. 8, e1002561. 
Ansideri F., Lange A., El-Gokha A., Boeckler F. M., Koch P. (2016) Fluorescence 
polarization-based assays for detecting compounds binding to inactive c-Jun N-
terminal kinase 3 and p38α mitogen-activated protein kinase. Anal. Biochem. 503, 
28–40. 
Arencibia J. M., Pastor-Flores D., Bauer A. F., Schulze J. O., Biondi R. M. (2013) AGC 
protein kinases: From structural mechanism of regulation to allosteric drug 
development for the treatment of human diseases. Biochim. Biophys. Acta - Proteins 
Proteomics 1834, 1302–1321. 
Asano T., Ikegaki I., Satoh S., Seto M., Sasaki Y. (1998) A protein kinase inhibitor, 
fasudil (AT-877): a novel approach to signal transduction therapy. Cardiovasc. Drug 
Rev. 16, 76–87. 
Beis I., Newsholme E. A. (1975) The contents of adenine nucleotides, phosphagens and 
some glycolytic intermediates in resting muscles from vertebrates and invertebrates. 
Biochem. J. 152, 23–32. 
Berglund E., Ubhayasekera S., Karlsson F., Akcakaya P., Aluthgedara W., Ahlen J., 
Fröbom R., et al. (2014) Intracellular concentration of the tyrosine kinase inhibitor 
imatinib in gastrointestinal stromal tumor cells. Anticancer drugs 25, 415–422. 
Bogoyevitch M. A., Barr R. K., Ketterman A. J. (2005) Peptide inhibitors of protein 
kinases-discovery, characterisation and use. Biochim. Biophys. Acta 1754, 79–99. 
Breen M. E., Steffey M. E., Lachacz E. J., Kwarcinski F. E., Fox C. C., Soellner M. B. 
(2014) Substrate activity screening with kinases: discovery of small-molecule 
substrate-competitive c-Src inhibitors. Angew. Chem., Int. Ed. Engl. 53, 7010–7013. 
Brock R. (2014) The uptake of arginine-rich cell-penetrating peptides: putting the 
puzzle together. Bioconjug. Chem. 25, 863–868. 
Bünzli J.-C. G., Piguet C. (2005) Taking advantage of luminescent lanthanide ions. 
Chem. Soc. Rev. 34, 1048–1077. 
Cao Y., He M., Gao Z., Peng Y., Li Y., Li L., Zhou W., et al. (2014) Activating hotspot 
L205R mutation in PRKACA and adrenal Cushing’s syndrome. Science 344, 913–917. 
Carlezon W. a., Duman R. S., Nestler E. J. (2005) The many faces of CREB. Trends 
Neurosci. 28, 436–445. 
Chen M., Liu A., Ouyang Y., Huang Y., Chao X., Pi R. (2013) Fasudil and its analogs: 
a new powerful weapon in the long war against central nervous system disorders? 
Expert Opin. Investig. Drugs 22, 537–550. 
Cheng X., Phelps C., Taylor S. S. (2001) Differential binding of cAMP-dependent 
protein kinase regulatory subunit isoforms Ialpha and IIbeta to the catalytic subunit. 
J. Biol. Chem. 276, 4102–4108. 
Cheng Y., Prusoff W. H. (1973) Relation between the inhibiton constant (Ki) and the 
concentration of inhibitor which causes 50 percent inhibiton (IC50) of an enzymatic 
reaction. Biochem. Pharmacol. 22, 3099–3108. 
Cohen P. (2002) Protein kinases-the major drug targets of the twenty-first century? Nat. 
Rev. Drug Discovery 1, 309–315. 
Copeland R. A. (2005) Evaluation of enzyme inhibitors in drug discovery. A guide for 




Davies S. P., Reddy H., Caivano M., Cohen P. (2000) Specificity and mechanism of 
action of some commonly used protein kinase inhibitors. Biochem. J. 351, 95–105. 
Delghandi M. P., Johannessen M., Moens U. (2005) The cAMP signalling pathway 
activates CREB through PKA, p38 and MSK1 in NIH 3T3 cells. Cell. Signal. 17, 
1343–1351. 
Demchenko A. P. (2015) Introduction to Fluorescence Sensing. Springer, Switzerland. 
Derossi D., Joliot A. H., Chassaing G., Prochiantz A. (1994) The third helix of the 
Antennapedia homeodomain translocates through biological membranes. J. Biol. 
Chem. 269, 10444–10450. 
Dranchak P., MacArthur R., Guha R., Zuercher W. J., Drewry D. H., Auld D. S., 
Inglese J. (2013) Profile of the GSK published protein kinase inhibitor set across 
ATP-dependent and-independent luciferases: implications for reporter-gene assays. 
PLoS One 8, e57888. 
Duchardt F., Fotin-Mleczek M., Schwarz H., Fischer R., Brock R. (2007) A 
comprehensive model for the cellular uptake of cationic cell-penetrating peptides. 
Traffic 8, 848–866. 
Ekambaram R., Enkvist E., Vaasa A., Kasari M., Raidaru G., Knapp S., Uri A. (2013) 
Selective bisubstrate inhibitors with sub-nanomolar affinity for protein kinase Pim-
1. ChemMedChem 8, 909–913. 
Elmquist A., Langel Ü. ̈ (2003) In vitro uptake and stability study of pVEC and its all-D 
analog. Biol. Chem. 384, 387–393. 
El-Sayed A., Futaki S., Harashima H. (2009) Delivery of macromolecules using 
arginine-rich cell-penetrating peptides: ways to overcome endosomal entrapment. 
AAPS J. 11, 13–22. 
Enkvist E., Lavogina D., Raidaru G., Vaasa A., Viil I., Lust M., Viht K., Uri A. (2006) 
Conjugation of adenosine and hexa-(D-arginine) leads to a nanomolar bisubstrate-
analog inhibitor of basophilic protein kinases. J. Med. Chem. 49, 7150–7159. 
Enkvist E., Viht K., Bischoff N., Vahter J., Saaver S., Raidaru G., Issinger O.-G., 
Niefind K., Uri A. (2012) A subnanomolar fluorescent probe for protein kinase CK2 
interaction studies. Org. Biomol. Chem. 10, 8645–8653. 
Erazo-Oliveras A., Muthukrishnan N., Baker R., Wang T. Y., Pellois J. P. (2012) 
Improving the endosomal escape of cell-penetrating peptides and their cargos: 
Strategies and challenges. Pharmaceuticals 5, 1177–1209. 
Fabbro D., Cowan-Jacob S. W., Moebitz H. (2015) Ten things you should know about 
protein kinases: IUPHAR Review 14. Br. J. Pharmacol. 172, 2675–2700. 
Fantozzi D. a, Taylor S. S., Howard P. W., Maurer R. a, Feramisco J. R., Meinkoth J. L. 
(1992) Effect of the thermostable protein kinase inhibitor on intracellular 
localization of the catalytic subunit of cAMP-dependent protein kinase. J. Biol. 
Chem. 267, 16824–16828. 
Friedrich M. W., Aramuni G., Mank M., Mackinnon J. A. G., Griesbeck O. (2010) 
Imaging CREB activation in living cells. J. Biol. Chem. 285, 23285–23295. 
Futaki S. (2006) Oligoarginine Vectors for Intracellular Delivery: Design and Cellular-
Uptake Mechanisms. Biopolymers 84, 241–249. 
Futaki S., Suzuki T., Ohashi W., Yagami T., Tanaka S., Ueda K., Sugiura Y. (2001) 
Arginine-rich peptides. An abundant source of membrane-permeable peptides having 
potential as carriers for intracellular protein delivery. J. Biol. Chem. 276, 5836–5840. 
Geissler D., Linden S., Liermann K., Wegner K. D., Charbonniere L. J., Hildebrandt N. 
(2014) Lanthanides and quantum dots as Forster resonance energy transfer agents 




Gonzalez de Castro D., Clarke P., Al-Lazikani B., Workman P. (2013) Personalized 
cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance. 
Clin. Pharmacol. Ther. 93, 252–259. 
Gower C. M., Chang M. E. K., Maly D. J. (2014) Bivalent inhibitors of protein kinases. 
Crit. Rev. Biochem. Mol. Biol. 49, 102–115. 
Graauw M. de, Hensbergen P., Water B. van de (2006) Phospho-proteomic analysis of 
cellular signaling. Electrophoresis 27, 2676–2686. 
Hagan A. K., Zuchner T. (2011) Lanthanide-based time-resolved luminescence 
immunoassays. Anal. Bioanal. Chem. 400, 2847–2864. 
Hanks S. K. (2003) Genomic analysis of the eukaryotic protein kinase superfamily: a 
perspective. Genome Biol. 4, 111. 
Hanks S. K., Hunter T. (1995) The eukaryotic protein kinase superfamily: kinase 
(catalytic) domain structure and classification. FASEB J. 9, 576–96. 
Harrison S., Das K., Karim F., Maclean D., Mendel D. (2008) Non-ATP-competitive 
kinase inhibitors - enhancing selectivity trough new inhibition strategies. Expert 
Opin. Drug Discov. 3, 761–774. 
Haystead T. A. J. (2006) The purinome, a complex mix of drug and toxicity targets. 
Curr. Top. Med. Chem. 6, 1117–1127. 
Heitz F., Morris M. C., Divita G. (2009) Twenty years of cell-penetrating peptides : 
from molecular mechanisms to therapeutics. Br. J. Pharmacol. 157, 195–206. 
Hemmilä I. (1991) Applications of fluorescence in immunoassays. John Wiley & Sons, 
New York. 
Hemmilä I., Laitala V. (2005) Progress in lanthanides as luminescent probes. J. 
Fluoresc. 15, 529–542. 
Herbst K. J., Allen M. D., Zhang J. (2009) The cAMP-dependent protein kinase 
inhibitor H-89 attenuates the bioluminescence signal produced by Renilla 
Luciferase. PLoS One 4, e5642. 
Hermanson S. B., Carlson C. B., Riddle S. M., Zhao J., Vogel K. W., Nichols R. J., Bi 
K. (2012) Screening for Novel LRRK2 Inhibitors Using a High-Throughput TR-
FRET Cellular Assay for LRRK2 Ser935 Phosphorylation. PLoS One 7, e43580. 
Hidaka H., Inagaki M., Kawamoto S., Sasaki Y. (1984) Isoquinolinesulfonamides, 
novel and potent inhibitors of cyclic nucleotide dependent protein kinase and protein 
kinase C. Biochemistry 23, 5036–5041. 
Hill S. J., Baker J. G., Rees S. (2001) Reporter-gene systems for the study of G-protein-
coupled receptors. Curr. Opin. Pharmacol. 1, 526–532. 
Huang X. (2003) Fluorescence Polarization Competition Assay: The Range of 
Resolvable Inhibitor Potency Is Limited by the Affinity of the Fluorescent Ligand. J. 
Biomol. Screen. 8, 34–38. 
Hunter T. (2000) Signaling-2000 and beyond. Cell 100, 113–127. 
Hötzer B., Medintz I. L., Hildebrandt N. (2012) Fluorescence in nanobiotechnology: 
Sophisticated fluorophores for novel applications. Small 8, 2297–2326. 
Iyer G. H., Taslimi P., Pazhanisamy S. (2008) Staurosporine-based binding assay for 
testing the affinity of compounds to protein kinases. Anal. Biochem. 373, 197–206. 
Jia Y., Quinn C. M., Kwak S., Talanian R. V (2008) Current in vitro kinase assay technol-
ogies: the quest for a universal format. Curr. Drug Discov. Technol. 5, 59–69. 
Jiang T., Xing B., Rao J. (2008) Recent developments of biological reporter technology 
for detecting gene expression. Biotechnol. Genet. Eng. Rev. 25, 41–75. 
Johannessen M., Delghandi M. P., Moens U. (2004a) What turns CREB on? Cell. 




Johannessen M., Delghandi M. P., Seternes O. M., Johansen B., Moens U. (2004b) 
Synergistic activation of CREB-mediated transcription by forskolin and phorbol 
ester requires PKC and depends on the glutamine-rich Q2 transactivation domain. 
Cell. Signal. 16, 1187–1199. 
Johannessen M., Moens U. (2007) Multisite phosphorylation of the cAMP response 
element-binding protein (CREB) by a diversity of protein kinases. Front. Biosci. 12, 
1814–1832. 
Johnson D. A., Akamine P., Radzio-Andzelm E., Madhusudan, Taylor S. S. (2001) 
Dynamics of cAMP-Dependent Protein Kinase. Chem. Rev. 101, 2243–2270. 
Johnson L. N. (2009) The regulation of protein phosphorylation. Biochem. Soc. Trans. 
37, 627–641. 
Jones S., Uusna J., Langel Ü., Howl J. (2016) Intracellular Target-Specific Accretion of 
Cell Penetrating Peptides and Bioportides: Ultrastructural and Biological Correlates. 
Bioconjug. Chem. 27, 121–129. 
Kasari M., Padrik P., Vaasa A., Saar K., Leppik K., Soplepmann J., Uri A. (2012) 
Time-gated luminescence assay using nonmetal probes for determination of protein 
kinase activity-based disease markers. Anal. Biochem. 422, 79–88. 
Kaufmann H., Bailey J. E., Fussenegger M. (2001) Use of antibodies for detection of 
phosphorylated proteins separated by two-dimensional gel electrophoresis. 
Proteomics 1, 194–199. 
Kawaguchi Y., Takeuchi T., Kuwata K., Chiba J., Hatanaka Y., Nakase I., Futaki S. 
(2016) Syndecan-4 Is a Receptor for Clathrin-mediated Endocytosis of Arginine-
rich Cell-penetrating Peptides. Bioconjug. Chem. 27, 1119–1130. 
Kestav K., Lavogina D., Raidaru G., Chaikuad A., Knapp S., Uri A. (2015) Bisubstrate 
inhibitor approach for targeting mitotic kinase Haspin. Bioconjug. Chem. 26, 225–
234. 
Kim C., Vigil D., Anand G., Taylor S. S. (2006) Structure and dynamics of PKA 
signaling proteins. Eur. J. Cell Biol. 85, 651–654. 
Knapp M., Bellamacina C., Murray J. M., Bussiere D. E. (2006) Targeting cancer: the 
challenges and successes of structure-based drug design against the human 
purinome. Curr. Top. Med. Chem. 6, 1129–1159. 
Knight Z. A., Lin H., Shokat K. M. (2010) Targeting the cancer kinome throuhg 
polypharmacology. Nat. Rev. Cancer 10, 130–137. 
Knighton D. R., Zheng J., Eyck L. F. Ten, Ashford V. A., Xuong N.-H., Taylor S. S., 
Sowadski J. M. (1991a) Crystal structure of the catalytic subunit of cyclic adenosine 
monophosphate-dependent protein kinase. Sience 253, 407–414. 
Knighton D. R., Zheng J., Eyck L. F. Ten, Xuong N.-H., Taylor S. S., Sowadski J. M. 
(1991b) Structure of a peptide inhibitor bound to the catalytic subunit of cyclic AMP 
dependent protein kinase. Science. 253, 414–420. 
Koren E., Torchilin V. P. (2012) Cell-penetrating peptides: Breaking through to the 
other side. Trends Mol. Med. 18, 385–393. 
Kuijt J., Ariese F., Brinkman U. A. T., Gooijer C. (2003) Room temperature 
phosphorescence in the liquid state as a tool in analytical chemistry. Anal. Chim. 
Acta 488, 135–171. 
Kwan J., Ling A., Papp E., Shaw D., Bradshaw J. M. (2009) A fluorescence resonance 
energy transfer-based binding assay for characterizing kinase inhibitors: Important 
role for C-terminal biotin tagging of the kinase. Anal. Biochem. 395, 256–262. 




Lamba V., Ghosh I. (2012) New directions in targeting protein kinases: focusing upon 
true allosteric and bivalent inhibitors. Curr. Pharm. Des. 18, 2936–2945. 
Lavogina D., Enkvist E., Uri A. (2010a) Bisubstrate inhibitors of protein kinases: from 
principle to practical applications. ChemMedChem 5, 23–34. 
Lavogina D., Kalind K., Bredihhina J., Hurt M., Vaasa A., Kasari M., Enkvist E., 
Raidaru G., Uri A. (2012) Conjugates of 5-isoquinolinesulfonylamides and oligo-D-
arginine possess high affinity and selectivity towards Rho kinase (ROCK). Bioorg. 
Med. Chem. Lett. 22, 3425–3430. 
Lavogina D., Lust M., Viil I., König N., Raidaru G., Rogozina J., Enkvist E., Uri A., 
Bossemeyer D. (2009) Structural analysis of ARC-type inhibitor (ARC-1034) 
binding to protein kinase A catalytic subunit and rational design of bisubstrate 
analogue inhibitors of basophilic protein kinases. J. Med. Chem. 52, 308–321. 
Lavogina D., Nickl C. K., Enkvist E., Raidaru G., Lust M., Vaasa A., Uri A., Dostmann 
W. R. (2010b) Adenosine analogue-oligo-arginine conjugates (ARCs) serve as high-
affinity inhibitors and fluorescence probes of type I cGMP-dependent protein kinase 
(PKGIα). Biochim. Biophys. Acta - Proteins Proteomics 1804, 1857–1868. 
Lea W. a., Simeonov A. (2011) Fluorescence Polarization Assays in Small Molecule 
Screening. Expert Opin Drug Discov. 6, 17–32. 
Lebakken C. S., Kang H. C., Vogel K. W. (2007) A Fluorescence Lifetime – Based 
Binding Assay to Characterize Kinase Inhibitors. J. Biomol. Screen. 12, 828–841. 
Lebakken C. S., Riddle S. M., Singh U., Frazee W. J., Eliason H. C., Gao Y., Reichling 
L. J., Marks B. D., Vogel K. W. (2009) Development and applications of a broad-
coverage, TR-FRET-based kinase binding assay platform. J. Biomol. Screen. 14, 
924–935. 
Lee J. S., Tung C. (2010) Lipo-oligoarginines as effective delivery vectors to promote 
cellular uptake. Mol. Biosyst. 6, 2049–2055. 
Lee J. S., Tung C.-H. (2012) Enhancing the Cellular Delivery of Nanoparticles using 
Lipo-Oligoarginine Peptides. Adv. Funct. Mater. 22, 4924–4930. 
Letoha T., Keller-Pinter A., Kusz E., Kolozsi C., Bozso Z., Toth G., Vizler C., Olah Z., 
Szilak L. (2010) Cell-penetrating peptide exploited syndecans. Biochim. Biophys. 
Acta - Biomembr. 1798, 2258–2265. 
Li Y., Xie W., Fang G. (2008) Fluorescence detection techniques for protein kinase 
assay. Anal. Bioanal. Chem. 390, 2049–2057. 
Lin X., Murray J. M., Rico A. C., Wang M. X., Chu D. T., Zhou Y., Rosario M. Del, et 
al. (2006) Discovery of 2-pyrimidyl-5-amidothiophenes as potent inhibitors for 
AKT: Synthesis and SAR studies. Bioorganic Med. Chem. Lett. 16, 4163–4168. 
Lipka D. B., Wagner M.-C., Dziadosz M., Schnöder T., Heidel F., Schemionek M., 
Melo J. V, et al. (2012) Intracellular retention of ABL kinase inhibitors determines 
commitment to apoptosis in CML cells. PLoS One 7, e40853. 
Loog M., Uri A., Raidaru G., Järv J., Ek P. (1999) Adenosine-5’-carboxylic acid 
peptidyl derivatives as inhibitors of protein kinases. Bioorganic Med. Chem. Lett. 9, 
1447–1452. 
Lukanowska M., Howl J., Jones S. (2013) Bioportides: bioactive cell-penetrating 
peptides that modulate cellular dynamics. Biotechnol. J. 8, 918–30. 
Manning G., Plowman G. D., Hunter T., Sudarsanam S. (2002a) Evolution of protein 
kinase signaling from yeast to man. Trends Biochem. Sci. 27, 514–520. 
Manning G., Whyte D. B., Martinez R., Hunter T., Sudarsanam S. (2002b) The protein 




Mano H., Ishimoto T., Okada T., Toyooka N., Mori H. (2014) Discovery of Novel 
Adenylyl Cyclase Inhibitor by Cell-Based Screening. 37, 1689–1693. 
Manoharan G. B., Enkvist E., Uri A. (2016) Combining chemical and genetic 
approaches for development of responsive FRET-based sensor systems for protein 
kinases. Biophys. Chem. 211, 39–48. 
Mathis G. (1995) Probing molecular interactions with homogeneous techniques based 
on rare earth cryptates and fluorescence energy transfer. Clin. Chem. 41, 1391–1397. 
Mayr B. M., Canettieri G., Montminy M. R. (2001) Distinct effects of cAMP and 
mitogenic signals on CREB-binding protein recruitment impart specificity to target 
gene activation via CREB. Proc. Natl. Acad. Sci. U. S. A. 98, 10936–10941. 
Milletti F. (2012) Cell-penetrating peptides: Classes, origin, and current landscape. 
Drug Discov. Today 17, 850–860. 
Moore E. G., Samuel A. P. S., Raymond K. N. (2009) From antenna to assay: lessons 
learned in lanthanide luminescence. Acc. Chem. Res. 42, 542–552. 
Morris M. C. (2013) Fluorescent biosensors - Probing protein kinase function in cancer 
and drug discovery. Biochim. Biophys. Acta - Proteins Proteomics 1834, 1387–
1395. 
Nagai Y., Miyazaki M., Aoki R., Zama T., Inouye S., Hirose K., Iino M., Hagiwara M. 
(2000) A fluorescent indicator for visualizing cAMP-induced phosphorylation in 
vivo. Nat. Biotechnol. 18, 313–316. 
Nelson A. R., Borland L., Allbritton N. L., Sims C. E. (2007) Myristoyl-Based 
Transport of Peptides into Living Cells. Biochemistry 46, 14771–14781. 
Nies A. T., Schaeffeler E., Kuip H. van der, Cascorbi I., Bruhn O., Kneba M., Pott C., et 
al. (2014) Cellular uptake of imatinib into leukemic cells is independent of human 
organic cation transporter 1 (OCT1). Clin. Cancer Res. 20, 985–994. 
Nikolovska-Coleska Z., Wang R., Fang X., Pan H., Tomita Y., Li P., Roller P. P., et al. 
(2004) Development and optimization of a binding assay for the XIAP BIR3 domain 
using fluorescence polarization. Anal. Biochem. 332, 261–273. 
Nitulescu G. M., Margina D., Juzenas P., Peng Q., Olaru O. T., Saloustros E., Fenga C., 
Spandidos D. a., Libra M., Tsatsakis A. M. (2016) Akt inhibitors in cancer 
treatment: The long journey from drug discovery to clinical use. Int. J. Oncol. 48, 
869–885. 
Okumura N., Inoue R., Okazaki Y., Nakano S., Nakagawa H., Kinoshita S., Koizumi N. 
(2015) Effect of the Rho Kinase inhibitor Y-27632 on corneal endothelial wound 
healing. Investig. Ophthalmol. Vis. Sci. 56, 6067–6074. 
Olive D. M. (2004) Quantitative methods for the analysis of protein phosphorylation in 
drug development. Expert Rev. Proteomics 1, 327–341. 
Ono-Saito N., Niki I., Hidaka H. (1999) H-series protein kinase inhibitors and potential 
clinical applications. Pharmacol. Ther. 82, 123–31. 
Parang K., Cole P. A. (2002) Designing bisubstrate analog inhibitors for protein 
kinases. Pharmacol. Ther. 93, 145–157. 
Pearce L. R., Komander D., Alessi D. R. (2010) The nuts and bolts of AGC protein 
kinases. Nat. Rev. Mol. Cell Biol. 11, 9–22. 
Pflug A., Rogozina J., Lavogina D., Enkvist E., Uri A., Engh R. A., Bossemeyer D. 
(2010) Diversity of bisubstrate binding modes of adenosine analogue-oligoarginine 
conjugates in protein kinase a and implications for protein substrate interactions. J. 
Mol. Biol. 403, 66–77. 
Pooga M., Hällbrink M., Zorko M., Langel U. (1998) Cell penetration by transportan. 




Prével C., Pellerano M., Van T. N. N., Morris M. C. (2014) Fluorescent biosensors for 
high throughput screening of protein kinase inhibitors. Biotechnol. J. 9, 253–265. 
Rajendran M., Yapici E., Miller L. W. (2013) Lanthanide-Based Imaging of Protein − 
Protein Interactions in Live Cells. Inorg. Chem. 53, 1839–1853. 
Ramsey J. D., Flynn N. H. (2015) Cell-Penetrating Peptides Transport Therapeutics into 
Cells. Pharmacol. Ther. 154, 78–86. 
Rask-Andersen M., Zhang J., Fabbro D., Schiöth H. B. (2014) Advances in kinase 
targeting: current clinical use and clinical trials. Trends Pharmacol. Sci. 35, 604–
620. 
Rhodes N., Heerding D. a., Duckett D. R., Eberwein D. J., Knick V. B., Lansing T. J., 
McConnell R. T., et al. (2008) Characterization of an Akt kinase inhibitor with 
potent pharmacodynamic and antitumor activity. Cancer Res. 68, 2366–2374. 
Roskoski R. (2015) A historical overview of protein kinases and their targeted small 
molecule inhibitors. Pharmacol. Res. 100, 1–23. 
Rudolf A. F., Skovgaard T., Knapp S., Jensen L. J., Berthelsen J. (2014) A comparison 
of protein kinases inhibitor screening methods using both enzymatic activity and 
binding affinity determination. PLoS One 9, e98800. 
Räägel H., Lust M., Uri A., Pooga M. (2008) Adenosine-oligoarginine conjugate, a 
novel bisubstrate inhibitor, effectively dissociates the actin cytoskeleton. FEBS J. 
275, 3608–3624. 
Sadok A., McCarthy A., Caldwell J., Collins I., Garrett M. D., Yeo M., Hooper S., et al. 
(2015) Rho kinase inhibitors block melanoma cell migration and inhibit metastasis. 
Cancer Res. 75, 2272–2284. 
Sassone-Corsi P. (2012) The Cyclic AMP pathway. Cold Spring Harb. Perspect. Biol. 
4, 1–4. 
Savage D. G., Antman K. H. (2002) Imatinib Mesylate - A New Oral Targeted Therapy. 
N. Engl. J. Med. 346, 683–693. 
Saville L., Spais C., Mason J. L., Albom M. S., Murthy S., Meyer S. L., Ator M. a, 
Angeles T. S., Husten J. (2012) Time-resolved fluorescence resonance energy 
transfer as a versatile tool in the development of homogeneous cellular kinase 
assays. Assay Drug Dev. Technol. 10, 551–7. 
Schenborn E., Groskreutz D. (1999) Reporter gene vectors and assays. Mol. Biotechnol. 
13, 29–44. 
Schwartz P. a, Murray B. W. (2011) Protein kinase biochemistry and drug discovery. 
Bioorg. Chem. 39, 192–210. 
Sharma S., Singh J., Ojha R., Singh H., Kaur M., Bedi P. M. S., Nepali K. (2016) 
Design strategies, structure activity relationship and mechanistic insights for purines 
as kinase inhibitors. Eur. J. Med. Chem. 112, 298–346. 
Shaywitz A. J., Greenberg M. E. (1999) CREB : a stimulus-induced transcription factor 
activated by a diverse array of extracellular signals. Annu. Rev. Biochem. 68, 821–
861. 
Shell J. R., Lawrence D. S. (2012) Proteolytic regulation of the mitochondrial cAMP-
dependent protein kinase. Biochemistry 51, 2258–64. 
Skålhegg B. S., Taskén K. (2000) Specificity in the cAMP/PKA signaling pathway. 
differential expression, regulation, and subcellular localization of subunits of PKA. 
Front. Biosci. 5, 678–693. 
Slatter a F., Campbell S., Angell R. M. (2013) Development of a fluorescence intensity 





Smith C. M., Radzio-Andzelm E., Madhusudan, Akamine P., Taylor S. S. (1999) The 
catalytic subunit of cAMP-dependent protein kinase: Prototype for an extended 
network of communication. Prog. Biophys. Mol. Biol. 71, 313–341. 
Smyth L. a., Collins I. (2009) Measuring and interpreting the selectivity of protein 
kinase inhibitors. J. Chem. Biol. 2, 131–151. 
Soini E., Hemmila I. (1979) Fluoroimmunoassay: Present status and key problems. 
Clin. Chem. 25, 353–361. 
Stebbins J. L., De S. K., Pavlickova P., Chen V., Machleidt T., Chen L., Kuntzen C., 
Kitada S., Karin M., Pellecchia M. (2011) Design and Characterization of a Potent 
and Selective Dual ATP- and Substrate-Competitive Subnanomolar Bidentate c-Jun. 
J. Med. Chem. 54, 6206–6214. 
Zaccolo M. (2004) Use of Chimeric Fluorescent Proteins and Fluorescence Resonance 
Energy Transfer to Monitor Cellular Responses. Circ. Res. 94, 866–873. 
Zhang J., Ma Y., Taylor S. S., Tsien R. Y. (2001) Genetically encoded reporters of 
protein kinase A activity reveal impact of substrate tethering. Proc. Natl. Acad. Sci. 
U. S. A. 98, 14997–15002. 
Zhang W., Morris G. Z., Beebe S. J. (2004) Characterization of the cAMP-dependent 
protein kinase catalytic subunit Cgamma expressed and purified from sf9 cells. 
Protein Expr. Purif. 35, 156–159. 
Zhou X., Herbst-Robinson K. J., Zhang J. (2012) Visualizing dynamic activities of 
signaling enzymes using genetically encodable FRET-based biosensors: From 
designs to applications. Methods Enzymol. 504, 317–340. 
Tamura M., Nakao H., Yoshizaki H., Shiratsuchi M., Shigyo H., Yamada H., Ozawa T., 
Totsuka J., Hidaka H. (2005) Development of specific Rho-kinase inhibitors and 
their clinical application. Biochim. Biophys. Acta 1754, 245–252. 
Tasken K. (2004) Localized Effects of cAMP Mediated by Distinct Routes of Protein 
Kinase A. Physiol. Rev. 84, 137–167. 
Taylor S. S., Ilouz R., Zhang P., Kornev A. P. (2012) Assembly of allosteric 
macromolecular switches: lessons from PKA. Nat. Rev. Mol. Cell Biol. 13, 646–658. 
Taylor S. S., Radzio-Andzelm E., Madhusudan, Cheng X., Eyck L. Ten, Narayana N. 
(1999) Catalytic subunit of cyclic AMP-dependent protein kinase: structure and 
dynamics of the active site cleft. Pharmacol. Ther. 82, 133–141. 
Taylor S. S., Yang J., Wu J., Haste N. M., Radzio-Andzelm E., Anand G. (2004) PKA: 
A portrait of protein kinase dynamics. Biochim. Biophys. Acta - Proteins Proteomics 
1697, 259–269. 
Turnham R. E., Scott J. D. (2016) Protein kinase A catalytic subunit isoform PRKACA; 
History, function and physiology. Gene 577, 101–108. 
Uehata M., Ishizaki T., Satoh H., Ono T., Kawahara T., Morishita T., Tamakawa H., et 
al. (1997) Calcium sensitization of smooth muscle mediated by a Rho-associated 
protein kinase in hypertension. Nature 389, 990–994. 
Uhlen M., Oksvold P., Fagerberg L., Lundberg E., Jonasson K., Forsberg M., Zwahlen 
M., et al. (2010) Towards a knowledge-based Human Protein Atlas. Nat. Biotechnol. 
28, 1248–1250. 
Uri A., Lust M., Vaasa A., Lavogina D., Viht K., Enkvist E. (2010) Bisubstrate 
fluorescent probes and biosensors in binding assays for HTS of protein kinase 
inhibitors. Biochim. Biophys. Acta 1804, 541–6. 
Uri A., Raidaru G., Subbi J., Padari K., Pooga M. (2002) Identification of the ability of 
highly charged nanomolar inhibitors of protein kinases to cross plasma membranes 




Vaasa A., Ligi K., Mohandessi S., Enkvist E., Uri A., Miller L. W. (2012) Time-gated 
luminescence microscopy with responsive nonmetal probes for mapping activity of 
protein kinases in living cells. Chem. Commun. (Camb). 48, 8595–7. 
Vaasa A., Lust M., Terrin A., Uri A., Zaccolo M. (2010) Small-molecule FRET probes 
for protein kinase activity monitoring in living cells. Biochem. Biophys. Res. 
Commun. 397, 750–755. 
Vaasa A., Viil I., Enkvist E., Viht K., Raidaru G., Lavogina D., Uri A. (2009) High-
affinity bisubstrate probe for fluorescence anisotropy binding/displacement assays 
with protein kinases PKA and ROCK. Anal. Biochem. 385, 85–93. 
Walsh D. A., Perkins J. P., Krebs E. G. (1968) An adenosine 3’,5'-monophosphate-
dependent protein kinase from rabbit skeletal muscle. J. Biol. Chem. 243, 3763–
3766. 
Wandelen L. T. M. van, Ameijde J. van, Ismail-Ali A. F., Ufford H. C. L. Q. van, 
Vijftigschild L. A. W., Beekman J. M., Martin N. I., Ruijtenbeek R., Liskamp R. M. 
J. (2013) Cell-penetrating bisubstrate-based protein kinase C inhibitors. ACS Chem. 
Biol. 8, 1479–1487. 
Wang H., Li M., Lin W., Wang W., Zhang Z., Rayburn E. R., Lu J., et al. (2007) 
Extracellular activity of cyclic AMP-dependent protein kinase as a biomarker for 
human cancer detection: distribution characteristics in a normal population and 
cancer patients. Cancer Epidemiol. Biomarkers Prev. 16, 789–795. 
Vasconcelos L., Pärn K., Langel Ü. (2013) Therapeutic potential of cell-penetrating 
peptides. Ther. Deliv. 4, 573–591. 
Widmer N., Decosterd L. a, Csajka C., Leyvraz S., Duchosal M. A., Rosselet A., Rochat 
B., et al. (2006) Population pharmacokinetics of imatinib and the role of alpha-acid 
glycoprotein. Br. J. Clin. Pharmacol. 62, 97–112. 
Viht K., Saaver S., Vahter J., Enkvist E., Lavogina D., Sinijärv H., Raidaru G., Guerra 
B., Issinger O. G., Uri A. (2015) Acetoxymethyl Ester of Tetrabromobenzimidazole-
Peptoid Conjugate for Inhibition of Protein Kinase CK2 in Living Cells. Bioconjug. 
Chem. 26, 2324–2335. 
Viht K., Schweinsberg S., Lust M., Vaasa A., Raidaru G., Lavogina D., Uri A., Herberg 
F. W. (2007) Surface-plasmon-resonance-based biosensor with immobilized 
bisubstrate analog inhibitor for the determination of affinities of ATP- and protein-
competitive ligands of cAMP-dependent protein kinase. Anal. Biochem. 362, 268–
277. 
Viht K., Vaasa A., Raidaru G., Enkvist E., Uri A. (2005) Fluorometric TLC assay for 
evaluation of protein kinase inhibitors. Anal. Biochem. 340, 165–170. 
Vives E., Brodin P., Lebleus B. (1997) A Truncated HIV-1 Tat Protein Basic Domain 
Rapidly Translocates through the Plasma Membrane and Accumulates in the Cell 
Nucleus. J. Biol. Chem. 272, 16010–16017. 
Wu P., Nielsen T. E., Clausen M. H. (2015) FDA-approved small-molecule kinase 
inhibitors. Trends Pharmacol. Sci. 36, 422–439. 
Xi Y., Niu J., Shen Y., Li D., Peng X., Wu X. (2016) AT13148, a first-in-class multi-
AGC kinase inhibitor, potently inhibits gastric cancer cells both in vitro and in vivo. 
Biochem. Biophys. Res. Commun. Accepted Manuscript, 
DOI:10.1016/j.bbrc.2016.01.167. 
Yap T. A., Walton M. I., Grimshaw K. M., Poele R. H. Te, Eve P. D., Valenti M. R., 
Haven Brandon A. K. De, et al. (2012) AT13148 is a novel, oral multi-AGC kinase 
inhibitor with potent pharmacodynamic and antitumor activity. Clin. Cancer Res. 





My sincere gratitude goes to my supervisor Dr. Asko Uri for his guidance, 
support, and patience throughout the research studies. I am grateful for the 
opportunity to work as part of his research group. 
I would like to thank all the past and current research group members for the 
excellent scientific and friendly working atmosphere. I would like to express 
my gratitude for Angela, Marje, Kaido, Erki, and Darja for sharing their 
knowledge and broad experiences. I would also like to thank Hedi, Taavi, 
Kadri, Katrin, Jürgen, and Ganesh for all the help, advice, and positivity. 
Special thanks to Prof. Ago Rinken and to the members of his research 
group for interesting discussions, helpful suggestions, and ideas. 
I am grateful to Prof. Ugo Moens, Prof. Päivi Koskinen, and Prof. Dmitri 
Papkovsky for the opportunity to work in their laboratories during my studies. 
Last but not least my special gratitude goes to my family and friends for the 










Name: Marie Kriisa 
Date of birth: March 17, 1988 
Citizenship: Estonian 
Address:  University of Tartu, Institute of Chemistry 




2012 to present University of Tartu, PhD student in chemistry 
2010–2012 University of Tartu, MSc in chemistry 
2007–2010 University of Tartu, BSc in chemistry 
 
Professional self-improvement 
02.06.2014–16.07.2014 characterisation of photoluminescent ARC-Lum 
probes, using specialised equipment (time-resolved fluorescence reader, FLIM 
microscope, hypoxia chambers) and different (2D and 3D) cell models; 
University College Cork, Ireland 
18.08.2013–31.08.2013 working with various fluorescently labelled fusion 
proteins and studying their localisation together with ARC-probes in cells, using 
wide-field and confocal microscopy; University of Turku, Finland 
17.01.2011–16.03.2011  studying PKA signalling pathway and the 
regulation of phosphorylation balances in living cells with PK inhibitors; 
University of Tromsø, Norway 
 
Professional organization 
Since 2010 Member of Estonian Biochemical Society 
 
Scientific publications 
1. Enkvist, E., Kriisa, M., Roben, M., Kadak, G., Raidaru, G., Uri, A. 
(2009) Effect of the structure of adenosine mimic of bisubstrate-analog 
inhibitors on their activity towards basophilic protein kinases. Bioorganic 
and Medicinal Chemistry Letters, 19(21), 6098–6101. 
2. Enkvist, E., Vaasa, A., Kasari, M., Kriisa, M., Ivan, T., Ligi, K., 
Raidaru, G., Uri, A. (2011) Protein-induced long lifetime luminescence 
of non-metal probes. ACS Chemical Biology, 6(10), 1052–1062. 
3. Kriisa, M., Sinijärv, H., Vaasa, A., Enkvist, E., Kostenko, S., Moens, U., 
Uri, A. (2015) Inhibition of CREB phosphorylation by conjugates of 
adenosine analogues and arginine-rich peptides, inhibitors of PKA 






Nimi: Marie Kriisa 
Sünniaeg: 17. märts, 1988 
Kodakondsus: Eesti 
Aadress:  Tartu Ülikool, keemia instituut 




2012 to present Tartu Ülikool, doktoriõpe keemias 
2010–2012 Tartu Ülikool, MSc keemias 
2007–2010 Tartu Ülikool, BSc keemias 
 
Erialane enesetäiendus 
02.06.2014–16.07.2014 fotoluminestsentsomadustega ARC-Lum sondide 
iseloomustamine eriseadmete (aeglahutusega fluorestsentslugeja, konfokaalne 
fluorestsentsi ja fosforestsentsi eluea mõõtmisel põhinev mikroskoop, hüpoksia 
kamber) ja erinevate (2D ja 3D) rakumudelite abil; Corki Ülikool, Iirimaa 
18.08.2013–31.08.2013 fluorestsentsvalguga märgistatud liit-valkudega 
töötamine ning nende paiknemise uurimine rakkudes koos ARC-sondidega, 
kasutades laiväli ja konfokaalset fluorestsentsmikroskoopi; Turu Ülikool, 
Soome 
17.01.2011–16.03.2011  PKA signaaliradade tundmaõppimine ning 




Alates 2010 Eesti biokeemia seltsi liige 
 
Scientific publications 
1. Enkvist, E., Kriisa, M., Roben, M., Kadak, G., Raidaru, G., Uri, A. 
(2009) Effect of the structure of adenosine mimic of bisubstrate-analog 
inhibitors on their activity towards basophilic protein kinases. Bioorganic 
and Medicinal Chemistry Letters, 19(21), 6098–6101. 
2. Enkvist, E., Vaasa, A., Kasari, M., Kriisa, M., Ivan, T., Ligi, K., 
Raidaru, G., Uri, A. (2011) Protein-induced long lifetime luminescence 
of non-metal probes. ACS Chemical Biology, 6(10), 1052–1062. 
3. Kriisa, M., Sinijärv, H., Vaasa, A., Enkvist, E., Kostenko, S., Moens, U., 
Uri, A. (2015) Inhibition of CREB phosphorylation by conjugates of 
adenosine analogues and arginine-rich peptides, inhibitors of PKA 
catalytic subunit. ChemBioChem, 16(2), 312–319. 
99 
DISSERTATIONES CHIMICAE  
UNIVERSITATIS TARTUENSIS 
1. Toomas Tamm. Quantum-chemical simulation of solvent effects. Tartu, 
1993, 110 p. 
2. Peeter Burk. Theoretical study of gas-phase acid-base equilibria. Tartu, 
1994, 96 p. 
3. Victor Lobanov. Quantitative structure-property relationships in large 
descriptor spaces. Tartu, 1995, 135 p. 
4. Vahur Mäemets. The 17O and 1H nuclear magnetic resonance study of 
H2O in individual solvents and its charged clusters in aqueous solutions of 
electrolytes. Tartu, 1997, 140 p. 
5.  Andrus Metsala. Microcanonical rate constant in nonequilibrium distribu-
tion of vibrational energy and in restricted intramolecular vibrational 
energy redistribution on the basis of slater’s theory of unimolecular re-
actions. Tartu, 1997, 150 p. 
6. Uko Maran. Quantum-mechanical study of potential energy surfaces in 
different environments. Tartu, 1997, 137 p. 
7. Alar Jänes. Adsorption of organic compounds on antimony, bismuth and 
cadmium electrodes. Tartu, 1998, 219 p. 
8. Kaido Tammeveski. Oxygen electroreduction on thin platinum films and 
the electrochemical detection of superoxide anion. Tartu, 1998, 139 p. 
9. Ivo Leito. Studies of Brønsted acid-base equilibria in water and non-
aqueous media. Tartu, 1998, 101 p. 
10.  Jaan Leis. Conformational dynamics and equilibria in amides. Tartu, 1998, 
131 p. 
11.  Toonika Rinken. The modelling of amperometric biosensors based on oxi-
doreductases. Tartu, 2000, 108 p. 
12. Dmitri Panov. Partially solvated Grignard reagents. Tartu, 2000, 64 p.  
13. Kaja Orupõld. Treatment and analysis of phenolic wastewater with micro-
organisms. Tartu, 2000, 123 p. 
14. Jüri Ivask. Ion Chromatographic determination of major anions and 
cations in polar ice core. Tartu, 2000, 85 p. 
15. Lauri Vares. Stereoselective Synthesis of Tetrahydrofuran and Tetra-
hydropyran Derivatives by Use of Asymmetric Horner-Wadsworth- 
Emmons and Ring Closure Reactions. Tartu, 2000, 184 p.  
16. Martin Lepiku. Kinetic aspects of dopamine D2 receptor interactions with 
specific ligands. Tartu, 2000, 81 p. 
17. Katrin Sak. Some aspects of ligand specificity of P2Y receptors. Tartu, 
2000, 106 p. 
18. Vello Pällin. The role of solvation in the formation of iotsitch complexes. 
Tartu, 2001, 95 p. 
19.  Katrin Kollist. Interactions between polycyclic aromatic compounds and 
humic substances. Tartu, 2001, 93 p. 
100 
20. Ivar Koppel. Quantum chemical study of acidity of strong and superstrong 
Brønsted acids. Tartu, 2001, 104 p. 
21. Viljar Pihl. The study of the substituent and solvent effects on the acidity 
of OH and CH acids. Tartu, 2001, 132 p. 
22. Natalia Palm. Specification of the minimum, sufficient and significant set 
of descriptors for general description of solvent effects. Tartu, 2001, 134 p. 
23. Sulev Sild. QSPR/QSAR approaches for complex molecular systems. 
Tartu, 2001, 134 p. 
24. Ruslan Petrukhin. Industrial applications of the quantitative structure-
property relationships. Tartu, 2001, 162 p. 
25. Boris V. Rogovoy. Synthesis of (benzotriazolyl)carboximidamides and their 
application in relations with N- and S-nucleophyles. Tartu, 2002, 84 p. 
26. Koit Herodes. Solvent effects on UV-vis absorption spectra of some 
solvatochromic substances in binary solvent mixtures: the preferential 
solvation model. Tartu, 2002, 102 p. 
27. Anti Perkson. Synthesis and characterisation of nanostructured carbon. 
Tartu, 2002, 152 p. 
28. Ivari Kaljurand. Self-consistent acidity scales of neutral and cationic 
Brønsted acids in acetonitrile and tetrahydrofuran. Tartu, 2003, 108 p. 
29. Karmen Lust. Adsorption of anions on bismuth single crystal electrodes. 
Tartu, 2003, 128 p. 
30. Mare Piirsalu. Substituent, temperature and solvent effects on the alkaline 
hydrolysis of substituted phenyl and alkyl esters of benzoic acid. Tartu, 
2003, 156 p. 
31. Meeri Sassian. Reactions of partially solvated Grignard reagents. Tartu, 
2003, 78 p. 
32. Tarmo Tamm. Quantum chemical modelling of polypyrrole. Tartu, 2003. 
100 p. 
33. Erik Teinemaa. The environmental fate of the particulate matter and 
organic pollutants from an oil shale power plant. Tartu, 2003. 102 p. 
34. Jaana Tammiku-Taul. Quantum chemical study of the properties of 
Grignard reagents. Tartu, 2003. 120 p. 
35. Andre Lomaka. Biomedical applications of predictive computational  
chemistry. Tartu, 2003. 132 p. 
36. Kostyantyn Kirichenko. Benzotriazole – Mediated Carbon–Carbon Bond 
Formation. Tartu, 2003. 132 p. 
37. Gunnar Nurk. Adsorption kinetics of some organic compounds on bis-
muth single crystal electrodes. Tartu, 2003, 170 p. 
38. Mati Arulepp. Electrochemical characteristics of porous carbon materials 
and electrical double layer capacitors. Tartu, 2003, 196 p. 
39. Dan Cornel Fara. QSPR modeling of complexation and distribution of 
organic compounds. Tartu, 2004, 126 p. 
40. Riina Mahlapuu. Signalling of galanin and amyloid precursor protein 
through adenylate cyclase. Tartu, 2004, 124 p. 
101 
41. Mihkel Kerikmäe. Some luminescent materials for dosimetric applications 
and physical research. Tartu, 2004, 143 p. 
42. Jaanus Kruusma. Determination of some important trace metal ions in 
human blood. Tartu, 2004, 115 p. 
43. Urmas Johanson. Investigations of the electrochemical properties of poly-
pyrrole modified electrodes. Tartu, 2004, 91 p. 
44. Kaido Sillar. Computational study of the acid sites in zeolite ZSM-5. 
Tartu, 2004, 80 p. 
45. Aldo Oras. Kinetic aspects of dATPS interaction with P2Y1 receptor. 
Tartu, 2004, 75 p. 
46. Erik Mölder. Measurement of the oxygen mass transfer through the air-
water interface. Tartu, 2005, 73 p.  
47. Thomas Thomberg. The kinetics of electroreduction of peroxodisulfate 
anion on cadmium (0001) single crystal electrode. Tartu, 2005, 95 p. 
48. Olavi Loog. Aspects of condensations of carbonyl compounds and their 
imine analogues. Tartu, 2005, 83 p.  
49. Siim Salmar. Effect of ultrasound on ester hydrolysis in aqueous ethanol. 
Tartu, 2006, 73 p.  
50. Ain Uustare. Modulation of signal transduction of heptahelical receptors 
by other receptors and G proteins. Tartu, 2006, 121 p. 
51. Sergei Yurchenko. Determination of some carcinogenic contaminants in 
food. Tartu, 2006, 143 p.  
52. Kaido Tämm. QSPR modeling of some properties of organic compounds. 
Tartu, 2006, 67 p.  
53. Olga Tšubrik. New methods in the synthesis of multisubstituted hydra-
zines. Tartu. 2006, 183 p.  
54. Lilli Sooväli. Spectrophotometric measurements and their uncertainty in 
chemical analysis and dissociation constant measurements. Tartu, 2006,  
125 p. 
55. Eve Koort. Uncertainty estimation of potentiometrically measured ph and 
pKa values. Tartu, 2006, 139 p.  
56. Sergei Kopanchuk. Regulation of ligand binding to melanocortin receptor 
subtypes. Tartu, 2006, 119 p.  
57. Silvar Kallip. Surface structure of some bismuth and antimony single 
crystal electrodes. Tartu, 2006, 107 p. 
58. Kristjan Saal. Surface silanization and its application in biomolecule 
coupling. Tartu, 2006, 77 p. 
59. Tanel Tätte. High viscosity Sn(OBu)4 oligomeric concentrates and their 
applications in technology. Tartu, 2006, 91 p. 
60. Dimitar Atanasov Dobchev. Robust QSAR methods for the prediction of 
properties from molecular structure. Tartu, 2006, 118 p.  
61.  Hannes Hagu. Impact of ultrasound on hydrophobic interactions in 
solutions. Tartu, 2007, 81 p. 
102 
62. Rutha Jäger. Electroreduction of peroxodisulfate anion on bismuth 
electrodes. Tartu, 2007, 142 p. 
63. Kaido Viht. Immobilizable bisubstrate-analogue inhibitors of basophilic 
protein kinases: development and application in biosensors. Tartu, 2007,  
88 p. 
64. Eva-Ingrid Rõõm. Acid-base equilibria in nonpolar media. Tartu, 2007, 
156 p. 
65. Sven Tamp. DFT study of the cesium cation containing complexes relevant 
to the cesium cation binding by the humic acids. Tartu, 2007, 102 p. 
66. Jaak Nerut. Electroreduction of hexacyanoferrate(III) anion on Cadmium 
(0001) single crystal electrode. Tartu, 2007, 180 p.  
67. Lauri Jalukse. Measurement uncertainty estimation in amperometric 
dissolved oxygen concentration measurement. Tartu, 2007, 112 p. 
68. Aime Lust. Charge state of dopants and ordered clusters formation in 
CaF2:Mn and CaF2:Eu luminophors. Tartu, 2007, 100 p. 
69. Iiris Kahn. Quantitative Structure-Activity Relationships of environ-
mentally relevant properties. Tartu, 2007, 98 p. 
70. Mari Reinik. Nitrates, nitrites, N-nitrosamines and polycyclic aromatic 
hydrocarbons in food: analytical methods, occurrence and dietary intake. 
Tartu, 2007, 172 p. 
71. Heili Kasuk. Thermodynamic parameters and adsorption kinetics of orga-
nic compounds forming the compact adsorption layer at Bi single crystal 
electrodes. Tartu, 2007, 212 p. 
72. Erki Enkvist. Synthesis of adenosine-peptide conjugates for biological 
applications. Tartu, 2007, 114 p.  
73. Svetoslav Hristov Slavov. Biomedical applications of the QSAR approach. 
Tartu, 2007, 146 p. 
74. Eneli Härk. Electroreduction of complex cations on electrochemically 
polished Bi(hkl) single crystal electrodes. Tartu, 2008, 158 p.  
75. Priit Möller. Electrochemical characteristics of some cathodes for medium 
temperature solid oxide fuel cells, synthesized by solid state reaction 
technique. Tartu, 2008, 90 p.  
76. Signe Viggor. Impact of biochemical parameters of genetically different 
pseudomonads at the degradation of phenolic compounds. Tartu, 2008, 122 p. 
77. Ave Sarapuu. Electrochemical reduction of oxygen on quinone-modified 
carbon electrodes and on thin films of platinum and gold. Tartu, 2008,  
134 p.  
78. Agnes Kütt. Studies of acid-base equilibria in non-aqueous media. Tartu, 
2008, 198 p.  
79. Rouvim Kadis. Evaluation of measurement uncertainty in analytical che-
mistry: related concepts and some points of misinterpretation. Tartu, 2008, 
118 p. 
80.  Valter Reedo. Elaboration of IVB group metal oxide structures and their 
possible applications. Tartu, 2008, 98 p. 
103 
81.  Aleksei Kuznetsov. Allosteric effects in reactions catalyzed by the cAMP-
dependent protein kinase catalytic subunit. Tartu, 2009, 133 p. 
82. Aleksei Bredihhin. Use of mono- and polyanions in the synthesis of 
multisubstituted hydrazine derivatives. Tartu, 2009, 105 p. 
83. Anu Ploom. Quantitative structure-reactivity analysis in organosilicon 
chemistry. Tartu, 2009, 99 p.  
84. Argo Vonk. Determination of adenosine A2A- and dopamine D1 receptor-
specific modulation of adenylate cyclase activity in rat striatum. Tartu, 
2009, 129 p. 
85.  Indrek Kivi. Synthesis and electrochemical characterization of porous 
cathode materials for intermediate temperature solid oxide fuel cells. Tartu, 
2009, 177 p.  
86. Jaanus Eskusson. Synthesis and characterisation of diamond-like carbon 
thin films prepared by pulsed laser deposition method. Tartu, 2009, 117 p. 
87. Marko Lätt. Carbide derived microporous carbon and electrical double 
layer capacitors. Tartu, 2009, 107 p. 
88. Vladimir Stepanov. Slow conformational changes in dopamine transporter 
interaction with its ligands. Tartu, 2009, 103 p.  
89. Aleksander Trummal. Computational Study of Structural and Solvent 
Effects on Acidities of Some Brønsted Acids. Tartu, 2009, 103 p. 
90.  Eerold Vellemäe. Applications of mischmetal in organic synthesis. Tartu, 
2009, 93 p. 
91.  Sven Parkel. Ligand binding to 5-HT1A receptors and its regulation by 
Mg2+ and Mn2+. Tartu, 2010, 99 p. 
92.  Signe Vahur. Expanding the possibilities of ATR-FT-IR spectroscopy in 
determination of inorganic pigments. Tartu, 2010, 184 p. 
93. Tavo Romann. Preparation and surface modification of bismuth thin film, 
porous, and microelectrodes. Tartu, 2010, 155 p. 
94. Nadežda Aleksejeva. Electrocatalytic reduction of oxygen on carbon 
nanotube-based nanocomposite materials. Tartu, 2010, 147 p.  
95.  Marko Kullapere. Electrochemical properties of glassy carbon, nickel and 
gold electrodes modified with aryl groups. Tartu, 2010, 233 p. 
96. Liis Siinor. Adsorption kinetics of ions at Bi single crystal planes from 
aqueous electrolyte solutions and room-temperature ionic liquids. Tartu, 
2010, 101 p. 
97.   Angela Vaasa. Development of fluorescence-based kinetic and binding 
assays for characterization of protein kinases and their inhibitors. Tartu 
2010, 101 p. 
98. Indrek Tulp. Multivariate analysis of chemical and biological properties. 
Tartu 2010, 105 p. 
99.  Aare Selberg. Evaluation of environmental quality in Northern Estonia by 
the analysis of leachate. Tartu 2010, 117 p. 
100. Darja Lavõgina. Development of protein kinase inhibitors based on 
adenosine analogue-oligoarginine conjugates. Tartu 2010, 248 p. 
104 
101. Laura Herm. Biochemistry of dopamine D2 receptors and its association 
with motivated behaviour. Tartu 2010, 156 p. 
102. Terje Raudsepp. Influence of dopant anions on the electrochemical pro-
perties of polypyrrole films. Tartu 2010, 112 p.  
103.  Margus Marandi. Electroformation of Polypyrrole Films: In-situ AFM 
and STM Study. Tartu 2011, 116 p. 
104. Kairi Kivirand. Diamine oxidase-based biosensors: construction and 
working principles. Tartu, 2011, 140 p. 
105. Anneli Kruve. Matrix effects in liquid-chromatography electrospray mass-
spectrometry. Tartu, 2011, 156 p. 
106. Gary Urb. Assessment of environmental impact of oil shale fly ash from 
PF and CFB combustion.  Tartu, 2011, 108 p. 
107. Nikita Oskolkov. A novel strategy for peptide-mediated cellular delivery 
and induction of endosomal escape. Tartu, 2011, 106 p. 
108. Dana Martin. The QSPR/QSAR approach for the prediction of properties of 
fullerene derivatives. Tartu, 2011, 98 p. 
109.  Säde Viirlaid. Novel glutathione analogues and their antioxidant activity. 
Tartu, 2011, 106 p. 
110.  Ülis Sõukand. Simultaneous adsorption of Cd2+, Ni2+, and Pb2+ on peat. 
Tartu, 2011, 124 p. 
111. Lauri Lipping. The acidity of strong and superstrong Brønsted acids, an 
outreach for the “limits of growth”: a quantum chemical study. Tartu, 
2011, 124 p. 
112. Heisi Kurig. Electrical double-layer capacitors based on ionic liquids as 
electrolytes. Tartu, 2011, 146 p. 
113. Marje Kasari. Bisubstrate luminescent probes, optical sensors and affinity 
adsorbents for measurement of active protein kinases in biological 
samples. Tartu, 2012, 126 p. 
114. Kalev Takkis. Virtual screening of chemical databases for bioactive mole-
cules. Tartu, 2012, 122 p. 
115. Ksenija Kisseljova. Synthesis of aza-β3-amino acid containing peptides 
and kinetic study of their phosphorylation by protein kinase A. Tartu, 
2012, 104 p. 
116. Riin Rebane. Advanced method development strategy for derivatization 
LC/ESI/MS. Tartu, 2012, 184 p. 
117. Vladislav Ivaništšev. Double layer structure and adsorption kinetics of 
ions at metal electrodes in room temperature ionic liquids. Tartu, 2012, 
128 p. 
118.  Irja Helm. High accuracy gravimetric Winkler method for determination 
of dissolved oxygen. Tartu, 2012, 139 p. 
119. Karin Kipper. Fluoroalcohols as Components of LC-ESI-MS Eluents: 
Usage and Applications. Tartu, 2012, 164 p. 
120. Arno Ratas. Energy storage and transfer in dosimetric luminescent 
materials. Tartu, 2012, 163 p. 
105 
121.  Reet Reinart-Okugbeni. Assay systems for characterisation of subtype-
selective binding and functional activity of ligands on dopamine recep-
tors. Tartu, 2012, 159 p. 
122.  Lauri Sikk. Computational study of the Sonogashira cross-coupling 
reaction. Tartu, 2012, 81 p. 
123. Karita Raudkivi. Neurochemical studies on inter-individual differences 
in affect-related behaviour of the laboratory rat. Tartu, 2012, 161 p. 
124.  Indrek Saar. Design of GalR2 subtype specific ligands: their role in 
depression-like behavior and feeding regulation. Tartu, 2013, 126 p. 
125. Ann Laheäär. Electrochemical characterization of alkali metal salt based 
non-aqueous electrolytes for supercapacitors. Tartu, 2013, 127 p.  
126.  Kerli Tõnurist. Influence of electrospun separator materials properties on 
electrochemical performance of electrical double-layer capacitors. Tartu, 
2013, 147 p. 
127.  Kaija Põhako-Esko. Novel organic and inorganic ionogels: preparation 
and characterization. Tartu, 2013, 124 p.  
128.  Ivar Kruusenberg. Electroreduction of oxygen on carbon nanomaterial-
based catalysts. Tartu, 2013, 191 p. 
129. Sander Piiskop. Kinetic effects of ultrasound in aqueous acetonitrile 
solutions. Tartu, 2013, 95 p. 
130.  Ilona Faustova. Regulatory role of L-type pyruvate kinase N-terminal 
domain. Tartu, 2013, 109 p. 
131. Kadi Tamm. Synthesis and characterization of the micro-mesoporous 
anode materials and testing of the medium temperature solid oxide fuel 
cell single cells. Tartu, 2013, 138 p.  
132.  Iva Bozhidarova Stoyanova-Slavova. Validation of QSAR/QSPR for 
regulatory purposes. Tartu, 2013, 109 p. 
133. Vitali Grozovski. Adsorption of organic molecules at single crystal 
electrodes studied by in situ STM method. Tartu, 2014, 146 p. 
134. Santa Veikšina. Development of assay systems for characterisation of 
ligand binding properties to melanocortin 4 receptors. Tartu, 2014, 151 p. 
135. Jüri Liiv. PVDF (polyvinylidene difluoride) as material for active 
element  of twisting-ball displays. Tartu, 2014, 111 p. 
136. Kersti Vaarmets. Electrochemical and physical characterization of 
pristine and activated molybdenum carbide-derived carbon electrodes for 
the oxygen electroreduction reaction. Tartu, 2014, 131 p. 
137. Lauri Tõntson. Regulation of G-protein subtypes by receptors, guanine 
nucleotides and Mn2+. Tartu, 2014, 105 p. 
138. Aiko Adamson. Properties of amine-boranes and phosphorus analogues 
in the gas phase. Tartu, 2014, 78 p. 
139. Elo Kibena. Electrochemical grafting of glassy carbon, gold, highly 
oriented pyrolytic graphite and chemical vapour deposition-grown graphene 
electrodes by diazonium reduction method. Tartu, 2014, 184 p.  
140.  Teemu Näykki. Novel Tools for Water Quality Monitoring – From Field 
to Laboratory. Tartu, 2014, 202 p. 
141.  Karl Kaupmees. Acidity and basicity in non-aqueous media: importance 
of solvent properties and purity. Tartu, 2014, 128 p. 
142. Oleg Lebedev. Hydrazine polyanions: different strategies in the synthesis 
of heterocycles. Tartu, 2015, 118 p. 
143.  Geven Piir. Environmental risk assessment of chemicals using QSAR 
methods. Tartu, 2015, 123 p. 
144.   Olga Mazina. Development and application of the biosensor assay for 
measurements of cyclic adenosine monophosphate in studies of G protein-
coupled receptor signalinga. Tartu, 2015, 116 p. 
145.  Sandip Ashokrao Kadam. Anion receptors: synthesis and accurate 
binding measurements. Tartu, 2015, 116 p. 
146.  Indrek Tallo. Synthesis and characterization of new micro-mesoporous 
carbide derived carbon materials for high energy and power density 
electrical double layer capacitors. Tartu, 2015, 148 p. 
147.  Heiki Erikson. Electrochemical reduction of oxygen on nanostructured 
palladium and gold catalysts. Tartu, 2015, 204 p. 
148.  Erik Anderson. In situ Scanning Tunnelling Microscopy studies of the 
interfacial structure between Bi(111) electrode and a room temperature 
ionic liquid. Tartu, 2015, 118 p. 
149.  Girinath G. Pillai. Computational Modelling of Diverse Chemical, Bio-
chemical and Biomedical Properties. Tartu, 2015, 140 p. 
150. Piret Pikma. Interfacial structure and adsorption of organic compounds at 
Cd(0001) and Sb(111) electrodes from ionic liquid and aqueous 
electrolytes: an in situ STM study. Tartu, 2015, 126 p. 
151. Ganesh babu Manoharan. Combining chemical and genetic approaches 
for photoluminescence assays of protein kinases. Tartu, 2016, 126 p. 
152. Carolin Siimenson. Electrochemical characterization of halide ion 
adsorption from liquid mixtures at Bi(111) and pyrolytic graphite 
electrode surface. Tartu, 2016, 110 p. 
153.  Asko Laaniste. Comparison and optimisation of novel mass spectrometry 
ionisation sources. Tartu, 2016, 156 p. 
154.  Hanno Evard. Estimating limit of detection for mass spectrometric 
analysis methods. Tartu, 2016, 224 p. 
155. Kadri Ligi. Characterization and application of protein kinase-responsive  
organic probes with triplet-singlet energy transfer. Tartu, 2016, 122 p. 
156.  Margarita Kagan. Biosensing penicillins’ residues in milk flows. Tartu, 
2016, 130 p. 
 
 
 
 
 
